

UC Davis

UC Davis Previously Published Works

Title

Genomic architecture of autism from comprehensive whole-genome sequence annotation.

Permalink

<https://escholarship.org/uc/item/2p58s24p>

Journal

Cell, 185(23)

Authors

Trost, Brett

Thiruvahindrapuram, Bhooma

Chan, Ada

et al.

Publication Date

2022-11-10

DOI

10.1016/j.cell.2022.10.009

Peer reviewed



Published in final edited form as:

Cell. 2022 November 10; 185(23): 4409–4427.e18. doi:10.1016/j.cell.2022.10.009.

Genomic Architecture of Autism From Comprehensive Whole-Genome Sequence Annotation

A full list of authors and affiliations appears at the end of the article.

SUMMARY

Fully understanding Autism Spectrum Disorder (ASD) genetics requires whole-genome sequencing (WGS). We present the latest release of the Autism Speaks MSSNG resource, which includes WGS data from 5,100 individuals with ASD and 6,212 non-ASD parents and siblings (total n=11,312). Examining a wide variety of genetic variants in MSSNG and the Simons Simplex Collection (SSC; n=9,205), we identified ASD-associated rare variants in 718/5,100 individuals with ASD from MSSNG (14.1%) and 350/2,419 from SSC (14.5%). Considering genomic architecture, 52% were nuclear sequence-level variants, 46% were nuclear structural variants (including copy number variants, inversions, large insertions, uniparental isodisomies, and tandem repeat expansions), and 2% were mitochondrial variants. Our study provides a guidebook for exploring genotype-phenotype correlations in families who carry ASD-associated rare variants and serves as an entry point to the expanded studies required to dissect the etiology in the ~85% of the ASD population that remain idiopathic.

In Brief

The latest release of the Autism Speaks MSSNG resource provides an expanded sample size and facilitates the comprehensive examination of the roles of many types of genetic variation in Autism Spectrum Disorder.

*Correspondence: stephen.scherer@sickkids.ca.

AUTHOR CONTRIBUTIONS


Conceptualization, B. Trost and S.W.S.; Methodology, B. Trost, B. Thiruvahindrapuram, A.J.S.C., W.E., E.J.H., L.O.L., M.S.R., D.R., M.Z., M.A., E. Aliyev, G.P., Z.W., J.R.M., J. Wei, M.G., E.K., N.M., C.L., L.J.S., J. Brian, A.K., T.W.F., J.A.S.V., K.A.F., B.A.F., R.W., R.K.C.Y., E. Anagnostou, N.S., and S.W.S.; Software, B. Trost, B. Thiruvahindrapuram, W.E., D.R., J. Whitney, M.B., R.V.P., T.N., G.P., O.H., G.K., J. Wei, W.W.L.S., N.D., J. Bates, J.F., J.N., H.W., P.M., A.A.B., U.K., S.K., J.V., M.V., J.G., and M.F.; Validation, S.L.; Investigation, B. Trost, B. Thiruvahindrapuram, A.J.S.C., W.E., E.J.H., J.L.H., L.O.L., M.S.R., D.R., M.Z., C. Somerville, R.S., M.A., E. Aliyev, Z.W., J.R.M., J. Wei, N.H., T.S., M.G., S. Ghaffari, E.J.Y., Q.D., C. Shum, L.D., C.A.B., A.R., V.A., B.A., N.C., S.D., X.D., M.L.Y.F., S.P., K.S., T.W., K.H., T.P., O.R., C.R.M., G.C., C. Sjaarda, and N.S.; Resources, M.J.S., M.H.Z., M.L., K.C., A.I., A.Y., P.A., L.G., D.G.A., J. Brian, M.E., S. Georgiades, D.S.M., S.O., J.S., C. Sjaarda, I.M.S., P.S., L.Z., M.E.S.L., E. Anagnostou, D.M.H., and S.W.S.; Data Curation, B. Thiruvahindrapuram, J.L.H., J. Whitney, M.B., R.V.P., J.F., J.N., H.W., P.M., A.A.B., U.K., S.K., J.V., M.V., J.G., V.S., M.Q., and M.F.; Visualization, B. Trost, W.E., J.L.H., and G.P.; Supervision, D.G., D.M.H., and S.W.S.; Project Administration, J.L.H., S.L.P., J.H., R.F.W., and M.F.; Funding Acquisition, S.W.S.

DECLARATION OF INTERESTS

E. Anagnostou has received consultation fees from Roche, Quadrant, and Oron; grant funding from Roche; in-kind supports from AMO Pharma and CRR; editorial honoraria from Wiley; and book royalties from APPI and Springer. She co-holds a patent for the device Anxiety Meter (patent # US20160000365A1). S.W.S. is on the Scientific Advisory Committee of Population Bio, serves as a Highly Cited Academic Advisor for King Abdulaziz University, and intellectual property from aspects of his research held at The Hospital for Sick Children are licensed to Athena Diagnostics and Population Bio.

Publisher's Disclaimer: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Graphical Abstract



Keywords

Autism Spectrum Disorder; neurodevelopmental disorders; whole-genome sequencing; copy number variation; structural variation; rare variants; polygenic risk scores; phenotype measures

INTRODUCTION

Autism Spectrum Disorder (ASD) is a neurodevelopmental condition whose core symptoms are social and communication difficulties, repetitive behaviors, and a restricted set of interests^{1,2}. ASD is observed in ~1–2% of individuals and is about four times more common in males than females^{3,4}. ASD is clinically heterogeneous, with some individuals exhibiting mild challenges and others experiencing severe symptoms and a range of co-occurring physical and mental health conditions⁵. Twin studies have estimated its heritability to be 64–91%⁶. ASD is also genetically heterogeneous, with a multitude of genes implicated^{7–10}. Rare or *de novo* high-impact genetic variants are typically identified in 5–20% of individuals with ASD, and more often in those with complex medical presentations^{11,12}. Different perspectives exist in the ASD community regarding the preferred language to refer to individuals with ASD, or autistic people; here we use the former term, although we recognize other preferences^{13–15}. Previous whole-genome sequencing (WGS) studies have examined the contributions of different classes of variants (Table S1A); however, they

typically analyzed only one or a few classes at a time and thus incompletely capture the genomic architecture of ASD.

This study had two objectives. The first was to introduce a substantial update to the Autism Speaks MSSNG resource (Figure 1). Compared to the previous release⁷, MSSNG now contains WGS data from twice as many individuals with ASD (5,100 versus 2,613) and total individuals (including family members; 11,312 versus 5,152), expanded genetic variant data, a redesigned web portal allowing the exploration of genotype and phenotype data, integration with the Terra cloud platform (<https://terra.bio>), and other enhancements (Table 1). Our second objective was to leverage MSSNG's WGS data to comprehensively examine the roles of many types of genetic variation in ASD, including common single nucleotide polymorphisms (SNPs), as well as rare and *de novo* single nucleotide variants (SNVs), short insertions/deletions (indels), mitochondrial DNA (mtDNA) variants, and structural variants (SVs, including copy number variants (CNVs), inversions, larger insertions, uniparental disomies (UPDs), and tandem repeat expansions (TREs)). These analyses encompass both coding and non-coding regions and both dominant and recessive modes of inheritance. We also used WGS data from 9,205 individuals from the Simons Simplex Collection (SSC)¹⁶ for replication and 2,504 unrelated population controls from the 1000 Genomes Project (1000G)¹⁷, for a total of >23,000 WGS samples analyzed (Table S1B).

RESULTS

Overview of MSSNG

All individuals with ASD in MSSNG meet diagnostic criteria according to the Diagnostic and Statistical Manual of Mental Disorders (DSM)¹, often supported by the Autism Diagnostic Interview-Revised (ADI-R)^{18,19} and/or the Autism Diagnostic Observation Schedule (ADOS)^{20,21}. MSSNG aggregates data from several cohorts and studies (Table S1C), including the Province of Ontario Neurodevelopmental Network (POND; <https://pond-network.ca>). Individuals of non-European ancestry comprise ~25% of MSSNG, including >2% each Admixed American, African, East Asian, and South Asian (Figure S1). For 3,565 of the individuals with ASD, genome sequences for both parents are available. MSSNG contains many multiplex (MPX) families, including 696 having two individuals with ASD and 88 with 3. MSSNG also includes 263 non-ASD siblings. Early samples (n=1,738) were sequenced using Complete Genomics technology²², while the rest were sequenced on Illumina platforms. Phenotype data based on 121 different tests are available (Table S1D).

MSSNG access is controlled by a Data Access Committee, and researchers can apply by submitting an ASD-related proposal⁷. As of July 2022, 342 researchers from 65 institutions in 20 countries have access, with many publishing their results (Table S1E). Data are stored on the Google Cloud Platform (GCP); large flat files (e.g., CRAM) are accessible via Cloud Storage buckets, while variant calls, annotations, sample metadata, and phenotype data are stored as BigQuery tables. The MSSNG portal (<https://research.mss.ng>), designed for the medical genomics community, allows variants to be queried based on sample, gene, or genomic region.

Enhancements to MSSNG

This release of MSSNG contains numerous improvements (Table 1). Reads are now aligned to GRCh38, and small variants are joint-called for improved accuracy (Illumina samples only). Also available are polygenic risk scores (PRS) and calls for many types of SVs. The MSSNG portal interface has been redesigned to accommodate the additional variant types (e.g., CNVs; Figure S2A), and the Integrative Genomics Viewer (IGV)²³-based read viewer displays CNV and SV calls for the entire family being examined. The new Phenotype Data Explorer allows users to analyze data at the level of the entire dataset, subsets (e.g., stratified by sex), or specific individuals (Figure S2B). Finally, MSSNG now supports accessing data via Terra (Figure S2C).

Exploring phenotype data can be challenging for users who lack extensive knowledge of the various tests, compounded by the fact that the tests (or versions thereof) may vary depending on when and where they were administered. To address these challenges, we developed several consensus phenotype measures, each encapsulating multiple data points into one easy-to-understand measure. For example, the Global Ability Consensus Estimate is calculated based on several measures related to IQ, verbal and nonverbal ability, and motor skills. Other consensus measures include the Adaptive Behaviour Standard Score, Socialization Standard Score, Full Scale IQ, and measures for common co-occurring conditions.

Discovery of ASD-associated genes

Previously, the Autism Sequencing Consortium (ASC) developed TADA+, an enhanced version of the transmission and *de novo* association (TADA) test²⁴, and applied it to whole-exome sequencing (WES) data from 6,430 trios, 5,556 cases, and 8,809 controls, identifying 102 ASD-associated genes with false discovery rate (FDR) <0.1⁸. To increase power, here we incorporated *de novo* variants from 12,375 additional trios from MSSNG and the Simons Foundation Powering Autism Research (SPARK)^{25,26} WES cohort (Table S2A–C). The number of exonic *de novo* variants per child were similar for ASC, MSSNG, and SPARK (Figure 2A). After incorporating the additional trios, we detected 134 ASD-associated genes with FDR <0.1 (Table S2D). Of these, 67 were identified by the previous TADA+ analysis, 67 were new, and 35 from the previous analysis no longer met the FDR threshold (Figure 2B, Table S2E). Many of the new genes (27/67) are not currently in the Simons Foundation Autism Research Initiative (SFARI) Gene database²⁷, providing novel molecules for study (Figure 2C–D). For most of the new genes, the evidence constituted a mix of *de novo* protein-truncating variants (PTVs), *de novo* damaging missense (DMis) variants, and excess PTVs in cases compared with controls (Figure 2E). However, for some genes the evidence consisted exclusively of PTVs (e.g., *MED13*, *TANC2*, *DMWD*) or *de novo* DMis variants (e.g., *ATP2B2*, *DMPK*, *PAPOLG*), providing insight into potential molecular mechanisms (e.g., haploinsufficiency for PTV-biased genes and gain-of-function or dominant-negative mechanisms for DMis-biased genes). Most new genes had high pLI scores (Figure 2F), suggesting haploinsufficiency as a common mechanism. To determine the contribution of MSSNG, we repeated this analysis using only ASC and SPARK data, which gave 120 ASD-associated genes (23 lost and nine gained relative to the full list) (Table S2D).

One new gene of interest was *DMPK*. RNA toxicity stemming from TREs in the 3'-UTR of *DMPK* cause myotonic dystrophy type I (DM1)²⁸, and individuals with DM1 have a higher incidence of ASD^{29,30}. In addition, we recently identified *DMPK* as one of the top candidate genes for association of TREs with ASD³¹. Here, five *de novo* DMis variants were detected in *DMPK* (Table S2D), suggesting that they may represent another mechanism by which this gene contributes to ASD susceptibility. Another interesting ASD-candidate gene was *GABRA1*, which encodes the most abundant α subunit of the GABA_A receptor, which mediates fast inhibitory neurotransmission³². Synaptic protein dysregulation and other alterations in the GABAergic system, including in the GABA_A receptors, have been implicated in ASD^{33,34}. Further, mice treated with valproic acid, one of the few suspected environmental susceptibility factors for ASD³⁵, exhibit ASD-like phenotypes and significantly decreased *GABRA1* expression³⁶.

Several new ASD-associated genes were located within CNV regions previously associated with neurodevelopmental disorders (NDDs). For example, *PRKG2*, *HNRNPD*, and *HNRDPL* are three of the five genes in the critical region for 4q21 microdeletion syndrome, which is associated with intellectual disability (ID) and impaired speech^{37,38}. *TSHZ1*, although primarily associated with a non-NDD phenotype, is in the 18q deletion region, which is characterized by ID and ASD³⁹. Other TADA+ genes within ASD-associated CNV regions included *CASZ1* (1p36), *TBCEL* (11q23.3), *PSMD11* (17q11.2), *RUNX1T1* (8q21.3), *ABCE1* (4q31.21-q31.22), and *PAPOLG* (2p16.1-p15), potentially pinpointing which genes in these regions contribute to their associated NDDs.

One of the highest-confidence genes from the original TADA+ analysis to “drop out” was *NRXN1*. In ASC, *NRXN1* had three *de novo* PTVs, one *de novo* DMis variant, and one PTV in a case (versus none in controls). However, zero *de novo* PTVs or DMis variants were found in *NRXN1* in MSSNG or SPARK. This reflects the limitation that TADA+ considers only sequence-level variants. Previous evidence for the involvement of *NRXN1* in ASD and other NDDs has largely been from deletions^{40,41}. *NRXN1* was also identified in our recent study of TREs in ASD³¹, underscoring the idea that all types of genetic variation must be considered, as is the case when using the EAGLE protocol for scoring ASD-relevant genes⁴².

Of the 134 genes, 106 were involved in gene networks. Based on gene connectivity, we classified the genes into eight functional modules (Figure 2G). The four largest modules were significantly enriched in the Gene Ontology (GO) terms synaptic signaling, chromatin organization, transcription co-regulator activity, and negative regulation of translation (Table S2F); 14/21 genes in the latter module were newly identified. Permutation tests showed that the connectivity of all pairs of genes in our network were greater than expected at random (Table S2G). To assess the specific contribution of MSSNG, we generated a network using the TADA+ genes derived from only ASC and SPARK. The resulting network was similar, except that the negative regulation of transcription module was no longer significant (Table S2F).

Detecting new ASD-associated genes may facilitate the identification of links with other disorders. While the overlap between ASD and attention deficit/hyperactivity disorder

(ADHD), obsessive-compulsive disorder (OCD), and ID are well-established^{43,44}, links between ASD and other disorders are less clear. Interestingly, several new ASD-associated genes have tentative links with neurodegenerative disorders, such as Alzheimer's disease, including *NR4A2*, *ATP2B2*, *EIF4E*, *EBF3*, *MARK2*, *EPOR*, *G3BP1*, *PLXNB1*, *APBB1*, and *ANP32A*. ASD and neurodegenerative diseases have common clinical features, including language, executive function, and motor impairments⁴⁵, and share some molecular pathomechanisms (e.g., synaptic deregulation).

Recessive events

To identify potential recessive events, we searched for homozygous and compound heterozygous (CH) PTVs and DMis variants. Only biallelic events with PTVs on both alleles (PTV-PTV events) were enriched in ASD (see subsequent section “Genomic architecture of rare coding variants in ASD”), so we focused on PTV-PTV events. A total of 198 genes harbored 1 PTV-PTV event and 33 had them in 2 unrelated individuals with ASD. In six multiplex families from MSSNG, two siblings with ASD shared the same PTV-PTV event (2 homozygous and 4 CH) in 6 distinct genes (*CASP5*, *DNAH14*, *DCHS2*, *C1orf229*, *DZANK1*, and *SMTNL1*). Interestingly, PTV-PTV events in *DNAH14* were found in another six individuals with ASD. *DNAH14* encodes axonemal dyneins, which are microtubule-associated motor protein complexes, and a recent study reported three unrelated individuals with NDDs having CH events in *DNAH14*⁴⁶. Ten genes with PTV-PTV events overlapped genes from the curated Genomics England neurology and neurodevelopmental disorders panel classified as having biallelic modes of inheritance (*ABCC6*, *BCAS3*, *CCDC40*, *DEAF1*, *GPR179*, *MMACHC*, *OBSCN*, *PRSS12*, *SORD*, and *TELO2*). *DEAF1* was also identified in the TADA+ analysis, suggesting that it may confer ASD susceptibility in a dose-dependent manner.

Structural variation

We used two pipelines to detect SVs: a read depth-based workflow⁴⁷, which detects CNVs 1 kb, and another employing split read and paired-end mapping-based algorithms, which detects deletions, duplications, insertions, and inversions 50 bp. We identified rare SVs falling into five categories: chromosomal abnormalities, genomic disorders, large or gene-rich CNVs not overlapping known genomic disorder regions, UPDs, and smaller SVs disrupting ASD/NDD genes (including the 134 TADA+ genes). Pathogenic SVs were detected in 6% of individuals with ASD. Most (96%) were deletions or duplications 1 kb; we found comparatively few pathogenic deletions or duplications <1 kb, large insertions, and inversions.

The WGS data also allowed deeper investigation of inversions and large insertions, and here we highlight two examples of such pathogenic variants. The first is a 71 bp *de novo* frameshift insertion in *SYNGAP1* comprised of 65 bp of mtDNA from *MT-CO3* and a 6 bp microduplication (Figure 3A–C). The insertion affects all known splice variants of *SYNGAP1* and to our knowledge is the first pathogenic mtDNA insertion reported in ASD. The second is a 13,472 bp inversion of unknown inheritance (parental samples unavailable) affecting *SCN2A* (Figure 3D–E).

Isodisomic UPD (isoUPD) results in homozygosity spanning some (partial) or all (complete) of a chromosome, potentially unmasking recessive variants. We identified two partial and three complete isoUPDs in individuals with ASD, with none in non-ASD siblings. None were within known imprinted domains. We lack platform-matched data to determine if this UPD rate is higher than in the general population; however, an increase was observed compared to a population study of 23andMe data⁴⁸ (ASD: 5/15,038 child-parent duos [0.033%]; population: 129/916,712 duos [0.014%]; Fisher's Exact Test: odds ratio (OR)=2.4, p=0.07). No heterodisomies were detected.

To demonstrate how WGS can aid interpretation of copy number gains, we resolved breakpoint junctions of duplications impacting ASD candidate genes in a subset of individuals with ASD in MSSNG. This process is largely manual, so we selected a subset of duplications and showed how their impact on gene structure and function can be evaluated by visualizing reads in IGV (STAR Methods). By fine-mapping the breakpoints of 375 duplications identified by read depth-based algorithms in 332 individuals, we identified 248 unique duplications ranging from 4.3 kb to 6.5 Mb (Table S3A). Most events remained at or near their locus of origin, including tandem duplications (192/248), likely non-allelic homologous recombination (NAHR)-mediated events (6/248), and complex duplications involving sequence transposition <100 kb from their locus of origin or inverted triplications without sequence transposition (14/248). Some complex duplications involved large-scale (>100 kb) transpositions (14/248) or interchromosomal transpositions (2/248), and 20/258 remained unresolved. Several duplications of uncertain clinical significance increased dosage of NDD genes, including *de novo* tandem events at *USP7* (OMIM: 602519) and *MEF2C* (OMIM: 600662).

Mitochondrial variation

We evaluated pathogenic variants, haplogroups, and heteroplasmy (variants present in only some copies of an individual's mtDNA genome) to study their association with ASD (STAR Methods). We identified 23 instances of known pathogenic variants with >5% heteroplasmy in individuals with ASD (Table S4A). Of these, 17 were *de novo*, defined as when maternal heteroplasmy was undetectable or <5%. The highest *de novo* heteroplasmy value was a 47% load of the m.13513G>A variant associated with Leigh Disease. The frequency of newly observed pathogenic heteroplasmies >5% in individuals with ASD (17/6,044) was significantly greater than the frequency of pathogenic heteroplasmies in mothers only (0/5,320) or fathers only (4/5,295) (χ^2 test: $p=6 \times 10^{-5}$). Two pathogenic heteroplasmies were identified in individuals without maternal sequencing data, so inheritance status could not be determined. We also identified four families for which a pathogenic variant was present at >5% heteroplasmy in both a mother and her child with ASD. In one, the child had a 49% load of the m.3243A>G variant associated with mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) (maternal load: 12%). Both mother and child had clinical symptoms consistent with MELAS. The average intergenerational change in heteroplasmy for pathogenic variants was an 11% shift toward the pathogenic allele in children with ASD. We also evaluated mtDNA variants causing homoplasmic disorders generally affecting vision and hearing only but found no association with ASD (Table S4B).

Certain macrohaplogroups have previously been associated with ASD susceptibility⁴⁹. However, we observed no significant difference in haplogroup distribution when comparing individuals with ASD with their fathers (n=4,821 duos) (Table S4C).

Finally, we evaluated the inheritance of heteroplasmy at all mtDNA positions. A prior study suggested increased transmission of heteroplasmy to children with ASD⁵⁰. However, we found no significant difference between the shifts from mother to children with ASD and the shifts from mother to non-ASD siblings in either MSSNG or SSC (Figure S3).

Genomic architecture of rare coding variants in ASD

We integrated the data above to give both high-level and detailed views of the genomic architecture of rare coding variants in ASD. We begin at a high level by comparing the burden of different variant types in individuals with ASD from either MSSNG or SSC with non-ASD siblings from SSC. *De novo* PTVs in constrained genes (gnomAD loss-of-function observed/expected upper bound fraction (LOEUF) <0.35) were significantly enriched in individuals with ASD, as were *de novo* DMis variants (Figure 4A). We observed no significant enrichment in inherited PTVs in constrained genes, but they were enriched in the 134 TADA+ genes for individuals with ASD in MSSNG, suggesting that PTVs in some TADA+ genes may have incomplete penetrance. No enrichment of inherited DMis variants was observed. Consistent with previous findings⁵¹, PTV-PTV biallelic events were significantly enriched in individuals with ASD, although we did not observe enrichment for events involving DMis variants (Figure 4A). Significant enrichment in ASD was observed for nearly all categories of SVs (Table S5A), including TREs³¹.

Next, we performed burden comparisons in MPX families (where inherited variation may have a larger role) versus simplex (SPX) (*de novo* variation). As expected, *de novo* PTVs in constrained genes were significantly depleted in MPX families (Table S5A). However, much of this signal came from siblings with ASD in MPX families rather than probands (the first child in the family to be diagnosed with ASD) (Figure 4B–C). This may reflect an ascertainment bias in which families having one child with ASD are more likely to have subsequent children evaluated and diagnosed⁵². We also observed a non-significant depletion of recessive events in MPX families. In some MPX families, individuals with ASD shared an ASD-associated rare variant, and in others, they had different variants (Figure S4), consistent with our previous findings⁵³.

Overall, ASD-associated rare variants were detected in ~14% of individuals with ASD, with the yield similar in MSSNG and SSC (Figure 4B). The largest contributor was dominant (where only one copy of the gene must be affected) sequence-level variants (51%). We observed no significant difference between ancestry groups in the overall prevalence of ASD-associated rare variants (Table S5B). Testing whether any class of rare variant differed in prevalence among groups, we detected an enrichment of TREs in individuals of African descent (OR=5.0, FDR=0.0004) (Table S5C).

To examine genotype-phenotype associations, we compared the distributions of four consensus phenotype measures—Adaptive Behavior Standard Score, Full Scale IQ, Global Ability Consensus Estimate, and Socialization Standard Score—in individuals with ASD

from MSSNG having each type of ASD-associated rare variant versus those with no such variant. Nearly all categories of ASD-associated rare variants were associated with lower scores for all four measures (Figure 4C), although an important caveat is that the four measures are correlated (Table S5D). Using logistic regression, dominant SNVs/indels were significantly associated with lower scores across all four measures, and TREs for all measures except the Global Ability Consensus Estimate. Some variant types, such as large or gene-rich CNVs, were consistently associated with lower scores but were not significant, possibly due to lack of power.

To give a detailed view of genomic architecture, we enumerated the genes and regions impacted (Figure 5 and Table S5E–M). Of the genes in the TADA+ list or that were ranked definitive by EAGLE curation⁴², those most frequently affected by dominant PTVs (*de novo* and inherited) and DMis variants (*de novo* only) in individuals with ASD included *PTEN*, *KDM5B*, *MIB1*, and *CHD8*. In addition to trisomy 21 and sex chromosome aneuploidies, several other chromosomal abnormalities were observed, including multiple translocations. The most frequently detected genomic disorders included CNVs at 16p11.2, 1q21.1, 15q11-q13, and 22q11.21. A variety of large or gene-rich CNVs not overlapping canonical genomic disorder regions were identified, including two each at 8p23.3-p23.1, 5p15.31-p15.2, and 2q23.3-q24.1. ASD-associated genes most affected by SVs included *NRXN1*, *PTCHD1-AS*, and *AUTS2*. Top genes for TREs were described previously³¹ and are recapitulated in Figure 5. Finally, the mtDNA genes most frequently affected by pathogenic variants were *MT-TL1* (MELAS) and *MT-ND6* (Leigh Disease).

Non-coding variants

We annotated rare sequence-level variants according to their impact on enhancers, promoters, topologically associating domains (TADs), and other regulatory elements (STAR Methods). We first performed transmission bias tests to compare the number of transmitted versus non-transmitted singleton variants (private to a particular family) impacting each non-coding element. The underlying hypothesis is that variants affecting elements related to ASD susceptibility will be over-transmitted from parents to individuals with ASD. After correcting for multiple testing, little enrichment was observed; however, in MSSNG, variants predicted to damage promoters were over-transmitted to individuals with ASD (Figure S5). In SSC, no over-transmission was observed in individuals with ASD or in non-ASD siblings. Similar results were obtained with variants having frequency <0.1% (Table S6A).

We also performed burden tests, in which the number of variants in a non-coding element were compared between individuals with ASD and non-ASD siblings. After correcting for multiple tests, no annotation classes were significantly enriched in ASD for rare, singleton, or *de novo* variants (Table S6B).

Polygenic risk scores

Much of our knowledge of ASD genetics is from studies of rare-inherited and *de novo* gene-disrupting variants. However, common variation also contributes to ASD heritability^{54,55}. Here, we used summary statistics from a recent ASD genome-wide association study (GWAS)⁵⁶ to calculate PRS in MSSNG, SSC, and 1000G. To assess

technical reproducibility, we compared PRS in 10 monozygotic twin pairs from MSSNG. Relative to the overall PRS range, all between-twin differences were small (Figure 6A). PRS distributions were similar in MSSNG, SSC, and 1000G (Figure 6B). Using individuals with ASD from MSSNG and SSC as cases and 1000G as controls, higher PRS was weakly associated with ASD susceptibility ($OR=1.03$, $p=2.5 \times 10^{-3}$; Nagelkerke's $R^2=0.0039$). Adjusting for sex, individuals with ASD in both MSSNG and SSC had higher mean PRS than non-ASD siblings in SSC (Figure 6C). No significant difference in PRS was observed between individuals with ASD in MSSNG versus SSC. Next, we performed a polygenic transmission disequilibrium test (pTDT), finding that PRS was significantly over-transmitted in individuals with ASD in both SSC (consistent with previous results⁵⁷) and MSSNG, but not in non-ASD siblings (Figure 6D). Stratifying by sex, PRS was significantly over-transmitted in males with ASD in both MSSNG and SSC as well as females in SSC (Figure S6B).

As similar trends were observed in MSSNG and SSC, we combined them to explore the extremes of the PRS distribution. We partitioned the children with ASD and individuals without ASD into PRS deciles and then computed ORs relative to the lowest decile. This was done using two control sets: non-ASD siblings from MSSNG and SSC ($n=666$ total individuals per decile) and individuals from 1000G ($n=551$ total individuals per decile). The ORs for the highest PRS decile were 1.32 and 1.53, respectively, relative to the lowest decile (Figure 6E).

MSSNG contains several large MPX families, affording the unique opportunity to explore PRS at the family level. We highlight two families, one with five children with ASD (FAM_1-0627-007) and the other with four (FAM_AU3889305) (Figure 6F). Other than one child in FAM_1-0627-007 with a 1.9 Mb *de novo* deletion at 16q23.3-q24.1, no ASD-associated rare variants were detected in the children. In both families, the children have a wide range of PRS (FAM_1-0627-007: -1.7 to 9.3 ; FAM_AU3889305: 1.3 to 7.7). Scores of 7.7 and 9.3 are in the 93rd and 96th percentiles, respectively, so if these children had been the only ones in their respective families, it may have been tempting to attribute their ASD to high polygenic risk. Given the additional context afforded by the lower PRS in the other children with ASD from these families, along with the non-ASD mother having the highest PRS in FAM_1-0627-007, there does not appear to be a basis for associating the ASD in these families solely with polygenic risk.

We leveraged the family structures in MSSNG and SSC to explore additional trends related to polygenic risk. In SSC sibling pairs (one with ASD and one without) whose PRS scores differed by more than one standard deviation, the sibling with ASD had the higher score 58% of the time (binomial test: $p=6.8 \times 10^{-4}$), and similarly for two standard deviations (65%; $p=0.01$). We detected no significant difference in mean PRS in individuals with ASD from MPX families compared with SPX families (Figure S6C), suggesting that ASD in MPX families may be more attributable to rare, high-impact variants. No significant difference was observed between PRS in mothers of children with ASD versus fathers (Figure S6D). We hypothesized that individuals in 1000G may have a lower mean PRS than parents in MSSNG and SSC, but no significant difference was observed (Figure S6E). No

significant association was detected between PRS and our consensus phenotype measures (Figure 6G).

ASD open science using Terra

Online data repositories have many advantages, including data persistence, format standardization, searchability, security, and version control. However, they are poorly suited to large files (e.g., CRAM) due to the time and expense required to download and store local copies of the data. Online code deposition also presents problems⁵⁸, as the code often fails to reproduce the published results or cannot be executed at all⁵⁹. With data storage, compute capabilities, and code in one place, cloud computing eliminates the need for each research group to store its own copy of the data and removes the disconnect between data and code⁶⁰. However, using and sharing cloud-based data can be technically challenging.

Terra (<https://terra.bio>) is a platform for researchers to collaboratively use cloud-based data. Its fundamental unit of organization is the “workspace”, each of which can contain multiple notebooks (code interleaved with its output) and workflows (chains of programs linked together, typically for computationally intensive operations). As MSSNG data are already stored in GCP, Terra is a natural fit for exploring cloud-based ASD research. To illustrate its use, we created two Terra workspaces. The first includes eight notebooks written in Python or R that help researchers get started accessing MSSNG data via Terra. It also contains two workflows that illustrate how to run ExpansionHunter⁶¹ and ExpansionHunter Denovo⁶². The second contains two notebooks that generate figures associated with our non-coding and PRS analyses. Researchers can inspect the underlying data, run code on those data themselves, and modify or extend the code by cloning the workspace. All notebooks and workflows are described in more detail in Table S1F.

DISCUSSION

For the latest release of MSSNG, we generated a rich resource of genetic data, including sequence-level, structural, and mitochondrial variants, tandem repeats, and polygenic risk scores. To meet the needs of researchers with different hypotheses or expertise, this information is accessible via several interfaces. The MSSNG portal is suitable for users without programming experience or who are interested in variants from a few genes or regions. The Terra integration is aimed at users with more complex research questions. Finally, advanced users can access MSSNG via BigQuery tables or flat files in GCP.

Importantly, MSSNG’s governance places its participants at the forefront of all decision-making. Clinicians who enrol families are heavily involved in the research study, and input is regularly sought from a Participant Advisory Committee. Annual meetings are held with hundreds of participating families discussing new developments, consents are regularly updated with participant input, and the most appropriate methods for interpreting and communicating genomic findings are contemplated by multidisciplinary teams^{42,63,64}. Research findings that meet standard clinical reporting criteria are returned to families accompanied by genetic counselling.

Our analysis of MSSNG yielded numerous findings that strengthen (or challenge) previous results or provide new insight into ASD genomic architecture. We identified 134 ASD-associated genes, as well as numerous ASD-associated variants that would have been difficult to detect without WGS. We found evidence challenging previous claims that certain mitochondrial haplogroups are associated with ASD and that heteroplasmy transmission is increased in children with ASD. No significant difference in the yield of ASD-associated rare variants among ancestry groups was observed. ASD-associated rare variation was related to lower scores in our consensus phenotype measures. We found that rare, dominant variation may play a greater role in MPX ASD, given the trend toward the depletion of rare, damaging recessive events and lack of enrichment for polygenic risk in these families. Finally, we report a comprehensive description of the contribution of different variant types to the genomic architecture of ASD, laying the groundwork for future studies into the ~85% of families who remain genetically unresolved (recognizing genetics may not be the only contributor).

One advantage of WGS compared with WES is the ability to explore non-coding variation. However, our analysis revealed limited enrichment of rare variants impacting non-coding elements in individuals with ASD (Figure S5), which is consistent with previous findings⁶⁵. In contrast to previous results⁶⁶, we observed no enrichment in *de novo* variants impacting promoter regions in SSC. Such observations highlight the challenges inherent in detecting robust and reproducible non-coding signals in a disorder as genetically heterogeneous as ASD, as different trends can be observed depending on the methodology used. They also highlight the need for even more ASD WGS data.

It has been suggested that PRS has, or will have, clinical or predictive utility for many different conditions^{67,68}. However, our PRS analysis (in particular, the low OR and R^2 , the small difference in mean PRS between individuals with and without ASD, and the modest enrichment of individuals with ASD in the highest PRS deciles) suggests that ASD PRS should be interpreted with caution and currently may not be informative at the level of individuals or families. Despite its current limitations, ASD PRS may eventually add to a more complete understanding of the mix of rare and common variant contributions to ASD^{69,70}. For instance, larger ASD GWASs, along with comparisons involving larger control cohorts such as the UK BioBank, may increase the proportion of variance explained. Further, PRS will likely become an important part of frameworks that model the multifactorial nature of ASD, such as liability threshold models⁵⁵.

This paper provides a significant new resource and analysis roadmap for ASD studies as genome sequencing begins to take its place in precision medicine applications⁷¹. With increasing emphasis being placed on genotype-phenotype correlations, individual-level understanding will be key to making earlier diagnoses, which may improve outcomes by allowing earlier treatment⁷². The molecular targets arising from this study may also eventually inform pharmacological interventions^{73,74}.

Limitations of the Study

By examining many types of genetic variants, we detected rare ASD-associated variants in ~14% of individuals with ASD. However, our study did not examine all possible genetic

factors. We did not investigate somatic variants or epigenetic contributors, although these have been investigated in smaller studies^{75–78}. We did not investigate recessive events other than those involving two sequence-level variants, such as a large deletion on one allele and a damaging sequence-level variant on the other. Finally, we were unable to identify genetic variants in complex regions of the genome that may only be accessible with long-read sequencing.

STAR METHODS

RESOURCE AVAILABILITY

Lead contact—Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Stephen Scherer (stephen.scherer@sickkids.ca).

Materials availability—This study did not generate new unique reagents.

Data and code availability

- Access to MSSNG and SFARI data can be obtained by completing data access agreements at <https://research.mss.ng> and <https://www.sfari.org/resource/sfari-base>, respectively. The 1000 Genomes Project WGS data are publicly available via Amazon Web Services (<https://docs.opendata.aws/1000genomes/readme.html>).
- All original code has been deposited at Zenodo and is publicly available as of the date of publication. The DOI is listed in the key resources table.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Cohorts comprising MSSNG—MSSNG contains data from several cohorts and studies (Table S1C). These include the ASD: Genomes to Outcomes Study, Autism Genetic Resource Exchange (AGRE), Autism Phenome Project, The Autism Simplex Collection (TASC), Autism Treatment Network, Baby Siblings Research Consortium, Infant Sibling Study, iTARGET, Pathways in ASD, the Province of Ontario Neurodevelopmental Network (POND), and Relating genes to Adolescent and Child mental Health (REACH). A breakdown of the samples corresponding to each study is given in Table S1C. The sex of each individual in MSSNG is given in Table S1B. The sample size of MSSNG (total number of individuals, including individuals with and without ASD) is 11,312, and the number of individuals with ASD is 5,100. Individuals meeting DSM diagnostic criteria for ASD were assigned to the ASD group, while individuals not meeting diagnostic criteria were assigned to the non-ASD group.

Ethics approval—Informed consent was obtained from all MSSNG participants. Approval for use of the AGRE data was obtained from WCG IRB (<https://www.wcgirb.com>). Approval for other cohorts was obtained from the Research Ethics or Institutional Review

Board of each recruiting site, including Montreal Children's Hospital-McGill University Health Centre, McMaster University-Hamilton Integrated, Memorial University-Eastern Health, Holland Bloorview Kids Rehabilitation Hospital, Queen's University, University of Alberta, University of British Columbia, IWK Health Centre, University of California Davis, University of California San Diego, University of Miami, and The Hospital for Sick Children.

METHOD DETAILS

Whole-genome sequencing of new MSSNG samples—Samples added to MSSNG since the previous release⁷ were sequenced on Illumina platforms. DNA was extracted from whole blood, lymphoblastoid cell lines, or (for a small number of samples) saliva. DNA quality was assessed using gel electrophoresis. Sample purity was assessed using the Nanodrop OD260/280 ratio, and DNA was quantitated using the Qubit High Sensitivity Assay. DNA libraries were prepared using the TruSeq Nano DNA Library Preparation Kit (Illumina), the same kit except omitting the PCR step, or the NxSeq[®] AmpFREE Low DNA Fragment Library Kit (Lucigen) following the manufacturers' instructions. Sequencing was performed on either the HiSeq 2000, HiSeq 2500, or HiSeq X platforms.

Detection of sequence-level variants in MSSNG—Alignment of reads against the GRCh38 reference sequence was performed using a pipeline conforming to the Centers for Common Disease Genomics (CCDG) functional equivalence standard⁷⁹. Sentieon v201808.01⁸⁰, which includes an optimized implementation of BWA⁸¹, was used to perform alignment, base quality score recalibration, and marking of duplicate reads, producing alignment files in CRAM format. The Sentieon implementation of the Genome Analysis Toolkit (GATK)⁸² was used to generate genomic VCF (gVCF) files for each sample. The gVCF files were combined to produce joint-genotyped VCF files (one per chromosome) containing variant calls from all samples. The gVCF files were divided into shards of ~50 Mb each to facilitate parallelization of the joint genotyping step. Variant metrics were generated using the CollectVariantCallingMetrics function of Picard. Workflows for read alignment and small variant detection are available as workflow description language (WDL) files on Dockstore (<https://dockstore.org/search?organization=DNASTACK>).

Replication and population control datasets—The Simons Simplex Collection (SSC)¹⁶, which includes WGS data from individuals with ASD and their family members, was used as a replication dataset. Alignment files and small variant calls for 9,205 SSC samples were downloaded from SFARI Base (<https://base.sfari.org>). Samples from the 1000 Genomes Project (1000G)¹⁷ were used as population control data. Alignment files for high-coverage sequencing data from 2,504 unrelated 1000G samples⁸³ were downloaded from Amazon Web Services, and small variant calls were downloaded from the European Bioinformatics Institute (http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000G_2504_high_coverage/working/20190425_NYGC_GATK). Variant detection and analysis of the SSC and 1000G data were performed using identical or near-identical pipelines as for MSSNG, allowing for true comparability across datasets. Specifically, the read alignment and small variant detection pipelines used to generate the downloaded data above were nearly identical to those used for MSSNG, as they used

BWA and GATK (version 3.5-0-g36282e) according to the CCDG functional equivalence standard. All other analyses of SSC and 1000G data (CNV detection, SV detection, mtDNA variant detection, PRS calculations, and variant annotations) were performed by our group using the same pipelines as used for MSSNG.

Experimental design—MSSNG was used as the discovery dataset and SSC as the replication dataset. Sample randomization and stratification, blinding, and sample-size estimation were not applicable in this study. All families having at least one child with ASD can be included in MSSNG; there are no exclusion criteria.

Small variant annotation, filtering, and *de novo* detection—Small variants were annotated using a custom ANNOVAR-based pipeline⁸⁴ using the parameters `--neargene 1 --splicing_threshold 2 --dbtype refseq --buildver hg38`. The database versions or download dates of the various annotation resources used are given in Table S7A.

To be labeled as high quality, calls were required to have FILTER="PASS" and depth (DP) ≥ 10 . Other criteria based on the genotype quality (GQ) and allelic fraction (AF) also had to be satisfied depending on the variant type. For heterozygous SNVs, also required were GQ ≥ 99 and $0.3 \leq AF < 0.8$. For heterozygous indels, also required were GQ ≥ 90 and $0.3 \leq AF < 0.8$. For homozygous SNPs and indels, also required were GQ ≥ 25 and $AF = 0.8$.

De novo variants were detected using DeNovoGear v1.1.1-313-geac3674⁸⁵. The Sentieon/GATK VCF file for each family was used as input to DeNovoGear. Autosomes and chromosome X in male and female children were called using separate models. Variants that failed Sentieon/GATK FILTER, had a non-reference parental genotype, or had filtering allele frequency (faf95) $> 1\%$ in GnomAD (exomes v2.1.1 and genomes v3.0) or frequency $> 1\%$ in parents were removed. Poorly sequenced sites ($< 95\%$ of parent samples genotyped) were also excluded. Putative *de novo* SNVs were defined as those with $pp_DNM > 0.95$ and GQ ≥ 99 . Putative *de novo* indels were defined as those with GQ > 90 for autosomes and X chromosome in females. To reduce the number of false positive *de novo* indels, we removed those with $< 30\%$ of reads supporting the indel call in the child or $> 10\%$ of reads supporting the alternative allele in a parent. For chromosome X in males, only the read support for the alternative allele in the mother was considered for filtering indels.

Comparison of variant counts—To assess the comparability of the sequence-level variants detected in the WGS samples used in this study, we stratified the samples into categories based on dataset (MSSNG, SSC, or 1000G), sequencing platform (Complete Genomics or Illumina HiSeq 2000/2500/X), and DNA library preparation method (PCR-based or PCR-free) and then examined the distributions of SNV and indel counts for various classes of variants (all, rare, rare exonic, rare DMis, rare PTVs, or *de novo*). Only high-quality variants (as defined in Methods) were included. All categories had similar distributions, except that Complete Genomics samples differed from the others in terms of indel counts, in particular with fewer indels overall but more *de novo* indels (Figure S7).

Ancestry determination—We extracted the genotypes for 57,984 positions from a previously published list (<https://www.tcag.ca/tools/1000genomes.html>) and retained

~43,000 positions for ADMIXTURE analysis⁸⁶ after removing variants with missing calls (genotyping rate <99%) in MSSNG, SSC, and 1000G. We refined population clusters by applying K-means clustering with K=7. Ancestry labels of 1000G samples were reassigned based on the population majority in the refined clusters. We then trained a random forest classifier using the 1000G samples with the reassigned labels. Ancestry labels in MSSNG and SSC were assigned using separate random forest classifiers. The ancestry assignment for the MSSNG samples was a consensus of the ADMIXTURE analysis and Google's genomic ancestry inference using deep learning (<https://cloud.google.com/blog/products/gcp/genomic-ancestry-inference-with-deep-learning>). Self-reported ancestry was used in cases where ADMIXTURE and the deep learning method were discrepant; if no self-reported ancestry was available, the individual was tagged as OTH (other).

Except for those involving PRS, all analyses in this paper used individuals from all ancestry groups, with population principal components being used to adjust for potential ancestry-related confounding effects where applicable. PRS analyses were performed only in individuals of European ancestry, because that is the population in which the original GWAS was performed (see the "Calculation of polygenic risk scores" section for more details).

Identification of damaging biallelic events—We identified damaging homozygous variants and compound heterozygous events in autosomes and classified each into one of two categories: PTV-PTV (PTVs on both alleles) or DMis- (DMis/PTV) (a DMis variant on one allele and either a PTV or a DMis variant on the other allele). Homozygous variants were identified in all individuals, while compound heterozygous events were identified only in individuals having both parents sequenced so that phase could be determined. Only variants with frequency <1% and that were high quality as defined previously were used. DMis variants were defined as those with MPC scores ≥ 2 , equivalent to MisB in the TADA+ analysis.

When evaluating the burden of damaging biallelic events, only individuals with both parents sequenced were considered. Potential ASD-associated damaging biallelic events were defined as those that (1) met the criteria described above; (2) were in a category (PTV-PTV or DMis- (DMis/PTV)) found to be enriched in individuals with ASD in our burden analysis; (3) were in genes in the Genomics England neurology and neurodevelopmental disorders panel labeled as having biallelic models of inheritance (n=3,149). In testing genes enriched in recessive events, we did not specifically test the subset of genes with low LOEUF scores, as this does not apply to recessive inheritance⁸⁷.

Detection of copy number variants—For Illumina data, CNVs ≥ 1 kb were detected using a pipeline⁴⁷ involving the algorithms ERDS⁸⁸ and CNVnator⁸⁹. CNV frequencies were calculated separately for three groups of samples—MSSNG parents sequenced by HiSeq X, MSSNG parents sequenced by HiSeq 2000/2500, and 1000 Genomes Project individuals. To avoid reliance on an external ASD cohort, we did not compute SSC parent frequencies. Samples with anomalous CNV counts (more than three standard deviations higher than the mean) were not included in frequency calculations. A threshold of 50% reciprocal overlap was used when calculating CNV frequencies. That is, if sample A

contained a CNV having at least 50% reciprocal overlap with some CNV B in the sample being annotated, then sample A was considered to have CNV B for frequency purposes.

Rare CNVs were defined as those with less than 1% frequency according to both ERDS and CNVnator in each of the three groups, as well as in MSSNG parents sequenced by Complete Genomics. High-quality CNVs were defined as those that were detected by both ERDS and CNVnator with at least 50% reciprocal overlap and for which less than 70% of the CNV overlapped assembly gaps, centromeres, and segmental duplications. “High-quality rare” (HQR) CNVs were defined as those that were both high-quality and rare. HQR CNVs were used for subsequent analysis. *De novo* CNVs were defined as HQR CNVs that were not detected by either ERDS or CNVnator in either parent. Further sample-level quality control was performed after identifying HQR and *de novo* CNVs. Samples with HQR counts more than three standard deviations higher than the mean were tagged as outliers. Due to the smaller number of individuals of non-European ancestry, this was done in European individuals only. The *de novo* CNV counts appeared to have a Poisson distribution, so we applied the Anscombe transformation to normalize the distribution. Samples with transformed counts more than three standard deviations higher than the mean (in any ancestry group) were tagged as outliers.

For Complete Genomics data, CNVs were detected using a proprietary pipeline provided by the company. Frequencies were calculated and rare CNVs were identified in the same way as for Illumina samples. All Complete Genomics CNVs were considered high-quality for the purposes of identifying HQR CNVs. Subsequent sample-level quality control was performed using the same method as for Illumina samples.

Detection of structural variants—Unlike for CNVs, we did not have an existing workflow for the detection of SVs from Illumina sequencing data. Thus, we developed a workflow specifically for this study by identifying promising candidate algorithms, evaluating the concordance and accuracy of those algorithms, selecting the most accurate combination of algorithms, and then determining effective filtering criteria to attain high sensitivity and specificity.

Dozens of algorithms for detecting SVs from short-read WGS data have been developed⁹⁰. We chose an initial set of algorithms for further evaluation based on the following criteria: all algorithms were required to predict most types of SVs (deletions, duplications, insertions, and inversions) and to have high accuracy based on a previous evaluation⁹⁰; at least some had to be under active development; and collectively use a variety of detection strategies (e.g., split reads, anomalous paired-end mapping, local assembly). The algorithms selected for further evaluation were DELLY⁹¹, GRIDSS⁹², LUMPY⁹³, Manta⁹⁴, SoftSV⁹⁵, SvABA⁹⁶, and Wham⁹⁷ (Table S7B).

We evaluated the accuracy of each algorithm using two methods. The first involved running the algorithms on WGS data from the HuRef⁹⁸, NA12878¹⁷, and HG002⁹⁹ genomes, and then comparing the SVs detected by each caller to SV benchmarks detected by orthogonal technologies (i.e., other than Illumina short-read sequencing). The HuRef benchmark was the same as used previously⁴⁷, but adding PBSV (<https://github.com/PacificBiosciences/>

pbsv) and Sniffles¹⁰⁰ calls from in-house 100x Pacific Biosciences long-read data. The NA12878 and HG002 benchmarks were derived from previous studies^{90,99}. The second method involved performing CRAM confirmation⁴⁷ on randomly selected calls from each algorithm in order to more fully evaluate specificity. Based on our evaluation, we found that Manta had the best combination of sensitivity and specificity. Although it made more false positives than Manta, we found that DELLY calls that overlapped with Manta calls were useful for giving added confidence to the Manta calls and were also useful for detecting inversions. Thus, we selected Manta and DELLY as the basis of our SV-detection workflow.

After algorithm selection, we determined whether the number of anomalously mapped paired-end reads and split reads supporting a given variant call could be used as filters to distinguish true calls from false ones. We found that neither variable was useful for this purpose. Next, for each variant type, we evaluated the sensitivity and specificity of various caller and stringency combinations (Manta PASS, DELLY PASS, Manta any, or DELLY any), and developed criteria that optimized sensitivity while maintaining good specificity (Table S7C).

Prior to calculating SV frequencies, we computed the number of SVs detected for each sample in 15 categories based on a combination of SV type (five categories: deletion, duplication, insertion, inversion, or overlapping deletion/duplication) and algorithm (three categories: detected by DELLY only, by Manta only, or by both DELLY and Manta). To reduce the impact of false positives, samples for which the call count was more than three standard deviations higher than the mean in two or more categories were excluded from the frequency calculations. As with CNVs, frequencies were calculated separately for MSSNG HiSeq X parents, MSSNG HiSeq 2000/2500 parents, and 1000 Genomes Project individuals. Frequencies were calculated separately for DELLY and Manta. A threshold of 90% reciprocal overlap was used when calculating SV frequencies. Rare CNVs were defined as those with less than 1% frequency in each of the three groups according to both Manta and DELLY, as well as in Complete Genomics MSSNG parents. SVs were defined as high-quality when they satisfied the filtering criteria derived as described above. HQR SVs were defined as for CNVs. For further quality control (QC) tagging, HQR and *de novo* counts were subjected to the Anscombe transformation, and samples were tagged as failing QC if they were an outlier for at least one of the five variant types (SVs detected by DELLY alone, Manta alone, or both Manta and DELLY were aggregated for each SV type prior to detecting outliers). QC based on HQR was performed only in samples of European ancestry, as other ancestry groups had fewer samples for comparison and generally had more rare SVs due to the European bias of the reference genome.

SVs in Complete Genomics samples were detected using the company's proprietary pipeline. Samples having an SV count that was an outlier in at least one SV category (deletion, distal-duplication, distal-duplication-inversion, interchromosomal, inversion, probable-inversion, and tandem-duplication) were excluded from the frequency calculation. Complete Genomics outliers were determined separately for different versions of the variant-detection software.

Inheritance assignment for copy number and structural variants—CNVs and SVs in children with both parents sequenced were tagged according to their putative inheritance. For CNVs, the child calls were compared to the father and mother calls independently. For each parent, for a given child call, all overlapping calls in the parent were identified. If the size of the child CNV was between half and twice the sum of the lengths of the overlapping parent calls, and the CNV type (deletion or duplication) matched, then the CNV was tagged as inherited from that parent. CNV calls in the child with no overlapping CNVs in the parent were tagged as having the potential to be *de novo*. If some overlapping calls were found in the parent, but the above size condition was not satisfied, then the child call was tagged for manual inspection of its *de novo* status. The inheritance assignments from both parents were then consolidated, with CNVs tagged as inherited for both parents retagged as ambiguous. Only CNVs tagged as potentially *de novo* for both parents were tagged as *de novo* after consolidation.

To minimize potential false positive *de novo* tags, child samples sequenced on Illumina platforms were compared with both the ERDS and CNVnator calls from the parent samples. For samples sequenced by Complete Genomics, a second CNV caller was not available, so additional filters (based on copy number estimates of the CNVs with flanking regions in the child and both parents) were used to minimize false positive *de novo* tagging.

SV inheritance was determined similarly, with the following differences designed to account for the more precise sizes and breakpoints afforded by the SV-detection methodology. As the members of a given family were joint-called for samples sequenced on Illumina platforms, a stringent 90% overlap threshold was used as the cutoff. Because samples sequenced by Complete Genomics were processed on a per-sample basis (i.e., not joint-called), a less stringent 50% overlap threshold was used.

Annotation and interpretation of copy number and structural variants—CNVs and SVs were annotated using a custom R script (v3.6.1) employing the GenomicRanges and data.table libraries. Gene annotations, genomic features, phenotype ontologies, and disease information were downloaded from various sources (Table S7D). SVs were interpreted according to ACMG and ClinGen guidelines^{101,102}. SVs classified as likely pathogenic or pathogenic (LP/P) are described as pathogenic. All pathogenic SVs were verified by CRAM confirmation⁴⁷, overlap with microarray findings, and/or Sanger sequencing. For *de novo* SVs, we verified the variant's absence in parents.

Resolution of duplication structures—To investigate the potential to use WGS data to resolve the structures of duplications and understand their impact on genes, we identified rare duplications in a subset of individuals with ASD in MSSNG that overlapped exons from a broad list of ASD candidate genes (Table S3B). Known recurrent genomic disorders (e.g., 15q11-q13 duplications) were excluded. Duplication structures were analyzed by visualizing CRAM files using IGV²³ and were classified as tandem or complex through manual inspection of paired-end reads and split reads at the duplication breakpoint junctions. Duplications having breakpoints mapping within homologous segmental duplications or LINE elements were considered likely NAHR events. Breakpoint junctions that could not be classified as tandem, complex, or likely NAHR events were considered unresolved. The

sequence-level breakpoint coordinates of tandem and complex duplications were determined through analysis of split read sequence in IGV and using BLAT¹⁰³. The last nucleotide of a split read before a deviation from the reference sequence was considered the sequence-level breakpoint of the duplication. Breakpoints that could not be resolved to the nucleotide level using split reads were estimated from the location of paired-end reads and read depth changes. The ERDS coordinates were used as an approximation of the true duplication breakpoints for likely NAHR and unresolved duplications. Duplications with identical breakpoints that were found in multiple related or unrelated individuals were deemed to represent a single unique event. The impact of each duplication on the ASD candidate gene(s) was annotated manually using the “NCBI RefSeq genes, curated subset” track of the UCSC Genome Browser¹⁰⁴. A duplication was considered to increase gene dosage when all RefSeq isoforms were fully contained within the duplication. The reading frame of intragenic duplications and fusion genes created at the breakpoints of a duplication were assessed using the UCSC Genome Browser.

Detection of uniparental disomies—Whole-chromosome and large segmental uniparental disomies (UPDs) were identified using SNPs and CNVs. For a subset of common SNPs, Mendelian errors were calculated using PLINK¹⁰⁵, and samples with excessive errors on a given chromosome were identified. Candidate regions were compared with CNV calls to exclude regions overlapping deletions. Putative isodisomies were further verified by checking that the SNP genotypes were mostly homozygous. Log R ratio (LRR) and B-allele frequency (BAF) plots were generated for the entire family to visualize UPDs.

Non-coding annotations—We used Ensembl Variant Effect Predictor (VEP) v102¹⁰⁶ and the October 2019 release of ANNOVAR⁸⁴ to perform non-coding variant annotations based on information from several databases. The variant data from each ASD WGS cohort were converted into ANNOVAR- and VEP-compatible format, with multi-allelic variants split and indels normalized to ensure correct matching of variants. Selected files from the non-coding variant databases (see below) were also converted to ANNOVAR-compatible format.

Regulatory features from Ensembl Regulatory Build (http://useast.ensembl.org/info/genome/funcgen/regulatory_build.html)¹⁰⁷ were added using VEP. Annotations related to promoters, enhancers, and their target genes were obtained from the GeneHancer database (geneHancerInteractionsDoubleElite, UCSC update January 2019)¹⁰⁸. Transcription factor binding sites and other regulatory elements were derived from the ReMap2020 non-redundant peak file (<http://remap.univ-amu.fr>)¹⁰⁹. Long non-coding RNA annotations were obtained from LNCipedia v5.2 (<https://lncipedia.org>)¹¹⁰. Small non-coding RNA annotations were acquired from DASHR v2.0 (<https://dashr2.lisanwanglab.org>)¹¹¹. Retrotransposon insertion polymorphism annotations were obtained from dbRIP (<https://dbrip.brocku.ca>)¹¹².

Topologically associating domain (TAD) boundaries were derived from a previous publication¹¹³, and five annotations were generated using the TAD boundaries. The first three annotations had possible values of 0, 1, or 2, depending on whether neither TAD flanking the boundary contained genes from a given gene list (0), one of the two

TADs did (1), or both did (2). The three gene lists used were the ASD-associated genes from our TADA+ analysis (134 genes), genes associated more generally with NDDs (1,250 genes), or genes intolerant to loss of function ($pLI > 0.9$) (2,867 genes)¹¹⁴. The 1,250 NDD-associated genes were derived from the literature (excluding those having autosomal recessive inheritance)^{8,115,116}, SFARI genes (score 1–3 plus syndromic), genes with ClinGen haploinsufficiency or triplosensitivity scores of 2 or 3¹¹⁷, and the Geisinger Developmental Brain Disorder Gene Database (<https://dbd.geisingeradmi.org>). The remaining two annotations were based on the “brain expression specificity” of the left and right TAD—that is, the fraction of genes in each TAD that are expressed in the brain based on Illumina Body Map 2.0 RNA-seq data. Specifically, let B_L and B_R be the proportion of genes that are brain-expressed in the left and right TAD, respectively. Then the first annotation represented the difference in brain expression specificity ($|B_L - B_R|$) and the second the sum of brain expression specificity ($B_L + B_R$).

All non-coding annotations and their sources are listed in detail in Table S6C.

Mitochondrial analysis—For samples sequenced on Illumina platforms, reads aligning to the mitochondrial genome were extracted and realigned to the revised Cambridge Reference Sequence (NC_012920) using BWA v0.7.8. Pileups were generated with SAMtools mpileup v1.1¹¹⁸, requiring the program to include duplicate reads and retaining all positions in the output. Custom scripts were developed to parse the mpileup output to determine the most frequently occurring non-reference base at each position. The heteroplasmic fractions were calculated and VCF files were generated. For samples sequenced by Complete Genomics, mitochondrial variants detected by the proprietary software were extracted. For both platforms, FASTA files replacing mitochondrial reference bases with alternative bases at sites where the heteroplasmic fraction was greater than or equal to 0.5 were also generated and haplogroups were predicted using HaploGrep v2.1.1¹¹⁹. The VCF files were annotated using ANNOVAR-based custom scripts with annotations from MitoMaster¹²⁰ (April 2019) and Ensembl v96.

Consensus phenotype measures—Consensus scores across several domains were calculated to facilitate the use of varied behavioral data across cohorts. These measures are not meant to replace the detailed and strategic work that a clinical psychologist or a computational scientist may choose to do with these data, but rather to provide reasonable ways of summarizing cognitive/behavioral data across domains of interest, especially for researchers who have less familiarity with the underlying tests. These measures represent a work in progress, and we welcome feedback on their design and utility as well as ideas for additional consensus measures. Below, we describe the consensus measures currently available in MSSNG.

Adaptive Behaviour Standard Score: Two measures capture this domain within MSSNG: Adaptive Behavior Assessment System (ABAS) and Vineland Adaptive Behavior Scales Survey Interview Form (Vineland). The computed score is the global adaptive composite (GAC) score from the ABAS or the adaptive behavior standard score from the Vineland. If more than one instrument is available, the most recent score is used. There is active work

being done to create a reliable correction strategy that will allow the use of scores from both instruments to be used as a continuous measure¹²¹.

Socialization Standard Score: This score is also calculated from the ABAS or Vineland, but the social composite score of the ABAS or the socialization standard score of the Vineland are used. If more than one instrument is available, the most recent score is used.

Full Scale IQ: While there are several IQ instruments in MSSNG, we include only Wechsler scales and Stanford-Binet under this category. Full Scale IQs (FSIQs) are prioritized over abbreviated IQs and Wechsler scales are prioritized over Stanford-Binet. Among FSIQs, the algorithm selects the most recent one if they are more than two years apart.

Global Ability Consensus Estimate: This score is intended to estimate global abilities when gold standard full IQ measures are not available. If a Full Scale IQ is available as per above, then this category is populated by that value. Otherwise, the following measures are used to populate this variable, in descending order of preference. The first choices are the Mullen Scales of Early Learning composite scores, followed by Merrill-Palmer (only when all three subdomain scores are available). Subsequently, nonverbal IQ can be used: Leiter International Performance Scale, followed by Raven's Progressive Matrices. Lastly, verbal standard scores from language assessments can be used in the following order: Clinical Evaluation of Language Fundamentals (CELF), Oral and Written Language Scales (OWLS), Preschool Language Scale (PLS), Expressive Vocabulary Test (EVT), and the Peabody Picture Vocabulary Test (PPVT). This is the category with the most noise and involving a clinical psychologist is highly recommended, depending on the research aim. Within each category, the most recent test is selected.

Co-occurring conditions (ADHD, anxiety, seizures, and gastrointestinal conditions): The available data across cohorts is extremely variable and may include everything from single items (e.g., parental report of a condition) to standardized instruments (e.g., Child Behavior Checklist (CBCL), Symptoms and Normal Behaviors (SWAN) score, Conners Comprehensive Behavior Rating Scales, Revised Children's Anxiety and Depression Scale (RCADS), and Spence Children's Anxiety Scale). In all categories, a non-stringent approach was taken so that if any available scores across any measures reflect clinical concern, then the co-occurring condition variable is labeled as true (e.g., ADHD=true). If none of the available measures suggest clinical concern, then the co-occurring condition variable is labeled as false (e.g., ADHD=false). These measures should not be considered evidence of diagnoses, but rather simply of clinical concern.

ADOS calibrated severity scores: To score past versions of item-level ADOS data, past protocol items corresponding to the most recent ADOS-2 version for each module were matched up and used. One item, "Hand and Finger and Other Complex Mannerisms", was originally two separate items in previous ADOS versions. For this item, the higher score of the two was used. For "Unusual Eye Contact", anything above 1 was recoded as 2, and zeros remained the same. After applying these transformations, the ADOS-2 algorithm^{122,123} was used to create domain-level sums and standardized severity scores. Missing items were

treated as zeros; however, no more than two missing items were allowed when computing the algorithm total. Furthermore, no more than two missing items were allowed when computing the Social Communication Domain total and no more than one missing item was allowed when computing the Restricted and Repetitive Behavior domain total. The ADOS calibrated severity scores are a work in progress and will be released once fully implemented (please contact the authors for more information).

QUANTIFICATION AND STATISTICAL ANALYSIS

ASD gene list generation—We generated a new ASD gene list by adding more trio data to a previous study by the ASC⁸, which used an enhanced version of the original TADA approach²⁴ to discover ASD-associated genes based on case-control data and *de novo* variants in trios. Specifically, we added *de novo* variants detected in individuals with ASD in trios from the MSSNG and SPARK^{25,26} cohorts. Variants from MSSNG and SPARK were annotated with Missense badness, PolyPhen-2, and constraint (MPC) scores¹²⁴ using dbNSFP¹²⁵. Genes with FDR <0.1 were considered to be ASD-associated.

Because the ASC variants were annotated using Variant Effect Predictor (VEP), whereas we annotated the MSSNG and SPARK variants using ANNOVAR, we compared the two annotation methods to ensure their classifications of PTVs and DMis variants were concordant. Upon re-annotating the ASC *de novo* variants with ANNOVAR, we observed only minor differences between the VEP and ANNOVAR annotations (Table S7E). We also observed high concordance between which missense variants had MPC scores in the ASC data and which were annotated with MPC scores using dbNSFP¹²⁵ (Table S7E). Finally, for missense variants having MPC scores from both methods (the vast majority), only 0.14% differed by more than 0.1. Collectively, the variant annotations for ASC and for MSSNG/SPARK were highly concordant.

Because variant quality score recalibration was not applied to the SPARK variant calls, we applied the hard filters recommended by the GATK development team (<https://gatk.broadinstitute.org/hc/en-us/articles/360035890471-Hard-filtering-germline-short-variants>). We considered recurrent *de novo* variants more likely to be false, so we manually inspected all recurrent *de novo* variants in IGV to verify their correctness and removed those deemed to be false. We also verified a randomly selected subset of non-recurrent *de novo* variants in IGV to verify their correctness and *de novo* status.

ASC variant coordinates were converted from GRCh37 to GRCh38 using the NCBI liftover tool. Sample overlap between MSSNG and SPARK was determined using PLINK¹⁰⁵. Because we only had access to *de novo* variants for ASC, sample overlap between ASC and MSSNG/SPARK could not be determined using PLINK. Thus, we conservatively removed any sample in MSSNG or SPARK that shared a *de novo* variant with an ASC sample. However, when the MSSNG/SPARK sample and the ASC sample were different sexes, both variants were retained. To ensure that there was no overlap between the MSSNG/SPARK *de novo* PTVs and PTVs in cases from the ASC case-control data, we downloaded the full set of variant-level data (https://atgu-exome-browser-data.s3.amazonaws.com/ASC/ASC_variant_results.tsv.bgz) from the ASC website (<https://asc.broadinstitute.org>), and then

identified PTVs in ASC cases that overlapped with *de novo* PTVs from MSSNG/SPARK. Because the TADA+ model gives more weight to *de novo* variants than case-control variants, we retained the MSSNG/SPARK *de novo* variants and discarded the overlapping ASC case-control variants. Due to the lack of sample-level information for the ASC case-control data, it was not possible to compare sample sex in order to potentially retain overlapping variants.

Gene network generation—A network diagram representing the ASD-associated genes identified in the TADA+ analysis was generated. For each gene, we used GeneMANIA¹²⁶ (dataset version gmdata-2021-04-29) to identify the 200 gene neighbors with the closest association based on protein-protein interactions and biological pathways using the “gene ontology biological process” weighting option. To select genes strongly connected to others, we retained only nodes connected by edges with a weighted Jaccard coefficient ≥ 0.33 . The network was visualized using Cytoscape¹²⁷.

Based on the gene connectivity, we partitioned the network into several modules. Each module was tested for pathway enrichment using Fisher’s Exact Tests to compare the sets of genes in each module with sets of genes described by pathway-related GO terms. To avoid GO terms with too few or too many genes, we used only terms with between 5 and 800 genes.

To determine whether the connectivity of the genes in our network was greater than expected by chance, we performed the following procedure for each edge E . For genes A and B connected by E , we calculated their Jaccard index (the fraction of genes connected to either A or B that are connected to both). Let N_A represent the number of genes connected to A , and similarly for N_B . We performed 1999 permutations, where each permutation involved randomly selecting a set of N_A genes and a set of N_B genes and calculating the Jaccard index of those sets. The random selections were made from the set of all genes connected to our TADA+ genes in GeneMania ($n=7,112$). The p-value for the permutation test was the proportion of the 2000 Jaccard indices (1999 random permutations plus the actual Jaccard index for A and B) that were greater than or equal to the actual Jaccard index.

Calculation of polygenic risk scores—We calculated PRS in individuals of European ancestry from the MSSNG, SSC, and 1000G cohorts using PLINK v1.9¹⁰⁵. For MSSNG, PRS was calculated only for individuals sequenced on Illumina platforms. We used summary statistics from a previously-published ASD meta-GWAS, which included the iPSYCH and Psychiatric Genomics Consortium (PGC) cohorts⁵⁶. Due to sample overlap between PGC and both MSSNG and SSC, we used summary statistics derived only from iPSYCH (13,076 cases and 22,664 controls).

We included only SNPs with minor allele frequency >0.05 (iPSYCH controls) and imputation quality score (INFO) >0.9 . To avoid potential strand conflicts, complementary SNPs were excluded. We also excluded SNPs with FILTER \neq PASS and those within the broad MHC region (chr6:25,000,000–35,000,000). Data from MSSNG, SSC and 1000G were merged prior to clumping, and only SNPs common to all three cohorts were retained. Clumping was performed with an r^2 threshold and radius of 0.1 and 500 kb, respectively.

PRS values were generated by including SNPs with p-value ≤ 0.1 , weighting by the additive scale effect (\log_{10} OR) of each variant, and then summing over the variants. Scores were centred to a mean of zero. In analyzing the PRS data, families in which a non-sibling member had an ASD diagnosis were excluded. PRS values for all P-value thresholds are given in Table S7F.

Non-coding transmission bias tests—We defined the odds ratio for over-transmission of non-coding variants with annotation A as $OR = (A_T/A_{NT}) / (O_T/O_{NT})$, where A_T is the number of transmitted non-coding variants with annotation A , A_{NT} is the corresponding number of non-transmitted variants, and O_T and O_{NT} are the total number of transmitted and non-transmitted non-coding variants, respectively, for all annotations other than A . To reduce noise, only variants with PhastCons score >0 were considered. To avoid the case where the expected transmission rate is not equal to 50% (for example, when both parents were heterozygous for a given variant, or one or both parents were homozygous), we included only variants for which one parent was heterozygous and the other did not have the variant. Complete Genomics samples were not included in the non-coding transmission tests because their genome-wide transmission rate differed from the expected 50%.

Burden tests—We used logistic regression to compare individuals with ASD with non-ASD siblings. The covariates used were sex, presence or absence of an ASD-associated rare variant, and population structure variables from ADMIXTURE⁸⁶. To correct for potential technical differences in variant detection between sequencing platforms (for example, HiSeq 2000 versus HiSeq X), we also used as a covariate the total number of variants of the type being tested. For instance, when testing the burden of *de novo* variants in promoters, the number of *de novo* variants genome-wide was used as a covariate. FDRs were calculated using the Benjamini-Hochberg (BH) method.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Brett Trost^{1,2}, Bhooma Thiruvahindrapuram¹, Ada J.S. Chan^{1,2}, Worrawat Engchuan^{1,2}, Edward J. Higginbotham^{1,2}, Jennifer L. Howe¹, Livia O. Loureiro^{1,2}, Miriam S. Reuter^{1,2,3}, Delnaz Roshandel², Joe Whitney¹, Mehdi Zarrei^{1,2}, Matthew Bookman⁴, Cherith Somerville⁵, Rulan Shaath¹, Mona Abdi^{6,7}, Elbay Aliyev⁶, Rohan V. Patel¹, Thomas Nalpathamkalam¹, Giovanna Pellecchia¹, Omar Hamdan¹, Gaganjot Kaur¹, Zhuozhi Wang¹, Jeffrey R. MacDonald¹, John Wei¹, Wilson W.L. Sung¹, Sylvia Lamoureux¹, Ny Hoang^{2,8,9,10}, Thanuja Selvanayagam^{2,8,10}, Nicole Deflaux⁴, Melissa Geng^{2,9}, Siavash Ghaffari^{1,2}, John Bates⁴, Edwin J. Young^{11,12}, Qiliang Ding⁵, Carole Shum^{1,2}, Lia D'abate^{1,2}, Clarissa A. Bradley^{2,13}, Annabel Rutherford^{1,2,9}, Vernie Aguda¹, Beverly Apresto¹, Nan Chen¹, Sachin Desai¹, Xiaoyan Du¹, Matthew L.Y. Fong¹, Sanjeev Pullenayegum¹, Kozue Samler¹, Ting Wang¹, Karen Ho¹, Tara Paton¹, Sergio L. Pereira¹, Jo-Anne Herbrick¹, Richard F. Wintle¹, Jonathan Fuerth¹⁴, Juti

Noppornpitak¹⁴, Heather Ward¹⁴, Patrick Magee¹⁴, Ayman Al Baz¹⁴, Usanthan Kajendirarajah¹⁴, Sharvari Kapadia¹⁴, Jim Vlasblom¹⁴, Monica Valluri¹⁴, Joseph Green¹⁴, Vicki Seifer¹⁵, Morgan Quirbach¹⁵, Olivia Rennie¹, Elizabeth Kelley^{16,17}, Nina Masjedi¹⁸, Catherine Lord¹⁸, Michael J. Szego^{9,19,20}, Ma'n H. Zawati²¹, Michael Lang²¹, Lisa J. Strug^{2,22}, Christian R. Marshall^{11,23}, Gregory Costain^{2,24,25}, Kristina Calli^{26,27}, Alana Iaboni²⁸, Afiqah Yusuf²⁹, Patricia Ambrozewicz^{8,30}, Louise Gallagher^{31,32,33,34}, David G. Amaral^{35,36}, Jessica Brian²⁸, Mayada Elsabbagh²⁹, Stelios Georgiades³⁷, Daniel S. Messinger³⁸, Sally Ozonoff^{35,36}, Jonathan Sebat³⁹, Calvin Sjaarda^{17,40}, Isabel M. Smith^{41,42}, Peter Szatmari^{43,32,34}, Lonnie Zwaigenbaum⁴⁴, Azadeh Kushki^{28,45}, Thomas W. Frazier^{15,46}, Jacob A.S. Vorstman^{2,34}, Khalid A. Fakhro^{6,7,47}, Bridget A. Fernandez^{48,49}, M.E. Suzanne Lewis^{26,27}, Rosanna Weksberg^{24,25}, Marc Fiume¹⁴, Ryan K.C. Yuen^{2,9}, Evdokia Anagnostou^{25,28}, Neal Sondheimer^{2,9,25}, David Glazer⁴, Dean M. Hartley¹⁵, Stephen W. Scherer^{1,2,9,50,51,*}

Affiliations

¹The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, ON M5G 0A4, Canada

²Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON M5G 0A4, Canada

³CGEn, The Hospital for Sick Children, Toronto, ON M5G 0A4, Canada

⁴Verily Life Sciences, San Francisco, CA 94080, USA

⁵Ted Rogers Centre for Heart Research, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada

⁶Department of Human Genetics, Sidra Medicine, Doha, Qatar

⁷College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar

⁸Autism Research Unit, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada

⁹Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada

¹⁰Department of Genetic Counselling, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada

¹¹Genome Diagnostics, Department of Paediatric Medicine, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada

¹²Department of Laboratory Medicine and Pathobiology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada

¹³Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON M5G 0A4, Canada

¹⁴DNASTack, Toronto, ON M5H 1T1, Canada

- ¹⁵Autism Speaks, Princeton, NJ 08540, USA
- ¹⁶Department of Psychology, Queen's University, Kingston, ON K7L 3N6, Canada
- ¹⁷Department of Psychiatry, Queen's University, Kingston, ON K7L7X3, Canada
- ¹⁸Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA 90024, USA
- ¹⁹Department of Family and Community Medicine, University of Toronto, Toronto, ON M5G 1V7, Canada
- ²⁰Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada
- ²¹Department of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada
- ²²Department of Statistical Sciences, University of Toronto, Toronto, ON M5S 3G3, Canada
- ²³Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada
- ²⁴Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
- ²⁵Department of Pediatrics, University of Toronto, Toronto, ON M5G 1X8, Canada
- ²⁶Department of Medical Genetics, University of British Columbia, Vancouver, BC V6H 3N1, Canada
- ²⁷BC Children's Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada
- ²⁸Holland Bloorview Kids Rehabilitation Hospital, Toronto, ON M4G 1R8, Canada
- ²⁹Montreal Neurological Institute, McGill University, Montreal, QC H3A 2B4, Canada
- ³⁰Department of Psychology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
- ³¹Department of Psychiatry, School of Medicine, Trinity College Dublin, Dublin 2, Ireland
- ³²Department of Psychiatry, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
- ³³Child, Youth and Family Services, The Centre for Addiction and Mental Health, Toronto, ON M6J 1H4, Canada
- ³⁴Department of Psychiatry, University of Toronto, Toronto, ON M5T 1R8, Canada
- ³⁵MIND Institute, University of California Davis, Sacramento, CA 95817, USA
- ³⁶Department of Psychiatry and Behavioral Sciences, University of California Davis, Sacramento, CA 95817, USA

- ³⁷Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON L8N 3K7, Canada
- ³⁸Department of Psychology, University of Miami, Miami, FL 33124, USA
- ³⁹Department of Psychiatry, University of California San Diego, La Jolla, CA 92093, USA
- ⁴⁰Queen's Genomics Lab at Ongwanada, Queen's University, Kingston, ON K7M 8A6, Canada
- ⁴¹Department of Pediatrics, Dalhousie University, Halifax, NS B3H 4R2, Canada
- ⁴²IWK Health Centre, Halifax, NS B3K 6R8, Canada
- ⁴³Centre for Addiction and Mental Health, Toronto, ON M6J 1H4, Canada
- ⁴⁴Department of Pediatrics, University of Alberta, Edmonton, AB T6G 1C9, Canada
- ⁴⁵Institute of Biomedical Engineering, University of Toronto, Toronto, ON M5S 3G9, Canada
- ⁴⁶Department of Psychology, John Carrol University, Cleveland, OH 44118, USA
- ⁴⁷Department of Genetic Medicine, Weill Cornell Medical College in Qatar, Doha, Qatar
- ⁴⁸Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA 90027, USA
- ⁴⁹Keck School of Medicine of USC, University of Southern California, Los Angeles, CA 90033, USA
- ⁵⁰McLaughlin Centre, Toronto, ON M5G 0A4, Canada
- ⁵¹Lead contact

ACKNOWLEDGMENTS

We thank the families participating in MSSNG, as well as the generosity of the donors who support this program. We acknowledge the resources of Autism Speaks and The Centre for Applied Genomics. We thank Anders Børghlum and Jakob Grove for providing the iPSYCH-only summary statistics and Kyle Satterstrom for providing TADA+ scripts. We are grateful to all of the families at the participating SSC and SPARK sites, as well as the principal investigators (A. Beaudet, R. Bernier, J. Constantino, E. Cook, E. Fombonne, D. Geschwind, R. Goin-Kochel, E. Hanson, D. Grice, A. Klin, D. Ledbetter, C. Lord, C. Martin, D. Martin, R. Maxim, J. Miles, O. Ousley, K. Pelphrey, B. Peterson, J. Piggot, C. Saulnier, M. State, W. Stone, J. Sutcliffe, C. Walsh, Z. Warren, E. Wijsman). We appreciate obtaining access to genetic and phenotypic data on SFARI Base. Approved researchers can obtain the SSC and SPARK datasets by applying at <https://base.sfari.org>. Funding was provided by the University of Toronto McLaughlin Centre, Genome Canada/Ontario Genomics, Genome BC, the Government of Ontario, the Canadian Institutes of Health Research (CIHR), the Canada Foundation for Innovation, Autism Speaks, Autism Speaks Canada, Brain Canada, Kids Brain Health Network, Qatar National Research Fund (NPRP10-0202-170320), Ontario Brain Institute, SickKids Foundation, and SFARI (570794, N.S. and S.S.). We thank Roche for the use of the HuRef PacBio sequencing data. B. Trost was supported by the CIHR Banting Postdoctoral Fellowship and the Canadian Open Neuroscience Platform Research Scholar Award. L.O.L. held the Lap-Chee Tsui Fellowship for Research Excellence. M.H.Z. acknowledges the support of the Fonds de recherche du Québec–Santé Junior 1 Research Scholar programme. J.S. and the REACH project were supported by grants from the National Institutes of Health (MH113715, MH119746, 1MH109501) and SFARI (606768). L.Z. holds the Stollery Children's Hospital Foundation Chair in Autism. M.E.S.L. holds a BC Children's Hospital Research Institute Investigator Grant Award. S.W.S. holds the Northbridge Chair in Pediatric Research at The Hospital for Sick Children and the University of Toronto.

INCLUSION AND DIVERSITY STATEMENT

We worked to ensure sex balance in the recruitment of human subjects (the male:female ratio for individuals with ASD in MSSNG closely mirrors the well-established 4:1 sex bias in ASD). We worked to ensure ethnic or other types of diversity in the recruitment of human subjects. We worked to ensure that the study questionnaires were prepared in an inclusive way. The author list of this paper includes contributors from the location where the research was conducted who participated in the data collection, design, analysis, and/or interpretation of the work.

REFERENCES

1. American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders 5th ed. (American Psychiatric Publishing).
2. Lord C, Brugha TS, Charman T, Cusack J, Dumas G, Frazier T, Jones EJJ, Jones RM, Pickles A, State MW, et al. (2020). Autism spectrum disorder. *Nat Rev Dis Primers* 6, 5. 10.1038/s41572-019-0138-4. [PubMed: 31949163]
3. Public Health Agency of Canada (2021). Autism Spectrum Disorder: Highlights from the 2019 Canadian Health Survey on Children and Youth (<https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/diseases-conditions/autism-spectrum-disorder-canadian-health-survey-children-youth-2019/autism-spectrum-disorder-canadian-health-survey-children-youth-2019.pdf>).
4. Centers for Disease Control and Prevention (2022). Autism and Developmental Disabilities Monitoring (ADDM) Network (<https://www.cdc.gov/ncbddd/autism/addm.html>). Centers for Disease Control and Prevention. <https://www.cdc.gov/ncbddd/autism/addm.html>.
5. Doshi-Velez F, Ge Y, and Kohane I (2014). Comorbidity clusters in autism spectrum disorders: An electronic health record time-series analysis. *Pediatrics* 133. 10.1542/peds.2013-0819.
6. Tick B, Bolton P, Happé F, Rutter M, and Rijdsdijk F (2016). Heritability of autism spectrum disorders: a meta-analysis of twin studies. *J Child Psychol Psychiatry* 57, 585–595. 10.1111/jcpp.12499. [PubMed: 26709141]
7. Yuen RKC, Merico D, Bookman M, Howe JL, Thiruvahindrapuram B, Patel RV, Whitney J, Deflaux N, Bingham J, Wang Z, et al. (2017). Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder. *Nat Neurosci* 20, 602–611. 10.1038/nn.4524. [PubMed: 28263302]
8. Satterstrom FK, Kosmicki JA, Wang J, Breen MS, De Rubeis S, An J-Y, Peng M, Collins R, Grove J, Klei L, et al. (2020). Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. *Cell* 180, 568–584.e23. 10.1016/j.cell.2019.12.036. [PubMed: 31981491]
9. Fu JM, Satterstrom FK, Peng M, Brand H, Collins RL, Dong S, Wamsley B, Klei L, Wang L, Hao SP, et al. (2022). Rare coding variation provides insight into the genetic architecture and phenotypic context of autism. *Nat Genet* 54, 1320–1331. 10.1038/s41588-022-01104-0. [PubMed: 35982160]
10. Zhou X, Feliciano P, Shu C, Wang T, Astrovskaia I, Hall JB, Obiajulu JU, Wright JR, Murali SC, Xu SX, et al. (2022). Integrating *de novo* and inherited variants in 42,607 autism cases identifies mutations in new moderate-risk genes. *Nat Genet* 54, 1305–1319. 10.1038/s41588-022-01148-2. [PubMed: 35982159]
11. Tammimies K, Marshall CR, Walker S, Kaur G, Thiruvahindrapuram B, Lionel AC, Yuen RKC, Uddin M, Roberts W, Weksberg R, et al. (2015). Molecular diagnostic yield of chromosomal microarray analysis and whole-exome sequencing in children with autism spectrum disorder. *JAMA* 314, 895–903. 10.1001/jama.2015.10078. [PubMed: 26325558]
12. Fernandez BA, and Scherer SW (2017). Syndromic autism spectrum disorders: moving from a clinically defined to a molecularly defined approach. *Dialogues Clin Neurosci* 19, 353–371. 10.31887/DCNS.2017.19.4/sscherer. [PubMed: 29398931]

13. Vivanti G (2020). Ask the editor: what is the most appropriate way to talk about individuals with a diagnosis of autism? *J Autism Dev Disord* 50, 691–693. 10.1007/s10803-019-04280-x. [PubMed: 31676917]
14. Bury SM, Jellett R, Spoor JR, and Hedley D (2020). “It defines who I am” or “It’s something I have”: what language do [autistic] Australian adults [on the autism spectrum] prefer? *J Autism Dev Disord*. 10.1007/s10803-020-04425-3.
15. Botha M, Hanlon J, and Williams GL (2021). Does language matter? identity-first versus person-first language use in autism research: a response to Vivanti. *J Autism Dev Disord*. 10.1007/s10803-020-04858-w.
16. Fischbach GD, and Lord C (2010). The Simons Simplex Collection: a resource for identification of autism genetic risk factors. *Neuron* 68, 192–195. 10.1016/j.neuron.2010.10.006. [PubMed: 20955926]
17. 1000 Genomes Project Consortium (2015). A global reference for human genetic variation. *Nature* 526, 68–74. 10.1038/nature15393. [PubMed: 26432245]
18. Lord C, Rutter M, and Le Couteur A (1994). Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. *J Autism Dev Disord* 24, 659–685. 10.1007/BF02172145. [PubMed: 7814313]
19. Kim SH, and Lord C (2012). New autism diagnostic interview-revised algorithms for toddlers and young preschoolers from 12 to 47 months of age. *J Autism Dev Disord* 42, 82–93. 10.1007/s10803-011-1213-1. [PubMed: 21384244]
20. Lord C, Rutter M, Goode S, Heemsbergen J, Jordan H, Mawhood L, and Schopler E (1989). Autism diagnostic observation schedule: a standardized observation of communicative and social behavior. *J Autism Dev Disord* 19, 185–212. 10.1007/BF02211841. [PubMed: 2745388]
21. Lord C, Risi S, Lambrecht L, Cook EH, Leventhal BL, DiLavore PC, Pickles A, and Rutter M (2000). The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. *J Autism Dev Disord* 30, 205–223. [PubMed: 11055457]
22. Drmanac R, Sparks AB, Callow MJ, Halpern AL, Burns NL, Kermani BG, Carnevali P, Nazarenko I, Nilsen GB, Yeung G, et al. (2010). Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. *Science* 327, 78–81. 10.1126/science.1181498. [PubMed: 19892942]
23. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, and Mesirov JP (2011). Integrative genomics viewer. *Nat Biotechnol* 29, 24–26. 10.1038/nbt.1754. [PubMed: 21221095]
24. He X, Sanders SJ, Liu L, De Rubeis S, Lim ET, Sutcliffe JS, Schellenberg GD, Gibbs RA, Daly MJ, Buxbaum JD, et al. (2013). Integrated model of *de novo* and inherited genetic variants yields greater power to identify risk genes. *PLoS Genet* 9, e1003671. 10.1371/journal.pgen.1003671. [PubMed: 23966865]
25. SPARK Consortium (2018). SPARK: A US cohort of 50,000 families to accelerate autism research. *Neuron* 97, 488–493. 10.1016/j.neuron.2018.01.015. [PubMed: 29420931]
26. Feliciano P, Zhou X, Astrovskaya I, Turner TN, Wang T, Brueggeman L, Barnard R, Hsieh A, Snyder LG, Muzny DM, et al. (2019). Exome sequencing of 457 autism families recruited online provides evidence for autism risk genes. *NPJ Genom Med* 4, 19. 10.1038/s41525-019-0093-8. [PubMed: 31452935]
27. Banerjee-Basu S, and Packer A (2010). SFARI Gene: an evolving database for the autism research community. *Dis Model Mech* 3, 133–135. 10.1242/dmm.005439. [PubMed: 20212079]
28. Sznajder EJ, and Swanson MS (2019). Short tandem repeat expansions and RNA-mediated pathogenesis in myotonic dystrophy. *Int J Mol Sci* 20, E3365. 10.3390/ijms20133365.
29. Ekström A-B, Hakenäs-Plate L, Samuelsson L, Tulinius M, and Wentz E (2008). Autism spectrum conditions in myotonic dystrophy type 1: a study on 57 individuals with congenital and childhood forms. *Am J Med Genet B Neuropsychiatr Genet* 147B, 918–926. 10.1002/ajmg.b.30698. [PubMed: 18228241]

30. Lagrue E, Dogan C, De Antonio M, Audic F, Bach N, Barnerias C, Bellance R, Cances C, Chabrol B, Cuisset J-M, et al. (2019). A large multicenter study of pediatric myotonic dystrophy type 1 for evidence-based management. *Neurology* 92, e852–e865. 10.1212/WNL.0000000000006948. [PubMed: 30659139]
31. Trost B, Engchuan W, Nguyen CM, Thiruvahindrapuram B, Dolzhenko E, Backstrom I, Mirceta M, Mojarad BA, Yin Y, Dov A, et al. (2020). Genome-wide detection of tandem DNA repeats that are expanded in autism. *Nature* 586, 80–86. 10.1038/s41586-020-2579-z. [PubMed: 32717741]
32. Zhu S, Noviello CM, Teng J, Walsh RM, Kim JJ, and Hibbs RE (2018). Structure of a human synaptic GABA_A receptor. *Nature* 559, 67–72. 10.1038/s41586-018-0255-3. [PubMed: 29950725]
33. Fatemi SH, Reutiman TJ, Folsom TD, and Thuras PD (2009). GABA(A) receptor downregulation in brains of subjects with autism. *J Autism Dev Disord* 39, 223–230. 10.1007/s10803-008-0646-7. [PubMed: 18821008]
34. Di J, Li J, O'Hara B, Alberts I, Xiong L, Li J, and Li X (2020). The role of GABAergic neural circuits in the pathogenesis of autism spectrum disorder. *Int J Dev Neurosci* 80, 73–85. 10.1002/jdn.10005. [PubMed: 31910289]
35. Christensen J, Grønberg TK, Sørensen MJ, Schendel D, Parner ET, Pedersen LH, and Vestergaard M (2013). Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. *JAMA* 309, 1696–1703. 10.1001/jama.2013.2270. [PubMed: 23613074]
36. Chau DK-F, Choi AY-T, Yang W, Leung WN, and Chan CW (2017). Downregulation of glutamatergic and GABAergic proteins in valproic acid associated social impairment during adolescence in mice. *Behav Brain Res* 316, 255–260. 10.1016/j.bbr.2016.09.003. [PubMed: 27614006]
37. Bonnet C, Andrieux J, Béri-Dexheimer M, Leheup B, Boute O, Manouvrier S, Delobel B, Copin H, Receveur A, Mathieu M, et al. (2010). Microdeletion at chromosome 4q21 defines a new emerging syndrome with marked growth restriction, mental retardation and absent or severely delayed speech. *J Med Genet* 47, 377–384. 10.1136/jmg.2009.071902. [PubMed: 20522426]
38. Hu X, Chen X, Wu B, Soler IM, Chen S, and Shen Y (2017). Further defining the critical genes for the 4q21 microdeletion disorder. *Am J Med Genet A* 173, 120–125. 10.1002/ajmg.a.37965. [PubMed: 27604828]
39. O'Donnell L, Soileau B, Heard P, Carter E, Sebold C, Gelfond J, Hale DE, and Cody JD (2010). Genetic determinants of autism in individuals with deletions of 18q. *Hum Genet* 128, 155–164. 10.1007/s00439-010-0839-y. [PubMed: 20499253]
40. Autism Genome Project Consortium (2007). Mapping autism risk loci using genetic linkage and chromosomal rearrangements. *Nat Genet* 39, 319–328. 10.1038/ng1985. [PubMed: 17322880]
41. Lowther C, Speevak M, Armour CM, Goh ES, Graham GE, Li C, Zeesman S, Nowaczyk MJM, Schultz L-A, Morra A, et al. (2017). Molecular characterization of *NRXN1* deletions from 19,263 clinical microarray cases identifies exons important for neurodevelopmental disease expression. *Genet Med* 19, 53–61. 10.1038/gim.2016.54. [PubMed: 27195815]
42. Schaaf CP, Betancur C, Yuen RKC, Parr JR, Skuse DH, Gallagher L, Bernier RA, Buchanan JA, Buxbaum JD, Chen C-A, et al. (2020). A framework for an evidence-based gene list relevant to autism spectrum disorder. *Nat Rev Genet* 21, 367–376. 10.1038/s41576-020-0231-2. [PubMed: 32317787]
43. Kushki A, Anagnostou E, Hammill C, Duez P, Brian J, Iaboni A, Schachar R, Crosbie J, Arnold P, and Lerch JP (2019). Examining overlap and homogeneity in ASD, ADHD, and OCD: a data-driven, diagnosis-agnostic approach. *Transl Psychiatry* 9, 318. 10.1038/s41398-019-0631-2. [PubMed: 31772171]
44. Thurm A, Farmer C, Salzman E, Lord C, and Bishop S (2019). State of the field: differentiating intellectual disability from autism spectrum disorder. *Front Psychiatry* 10, 526. 10.3389/fpsy.2019.00526. [PubMed: 31417436]
45. Khan SA, Khan SA, Narendra AR, Mushtaq G, Zahran SA, Khan S, and Kamal MA (2016). Alzheimer's disease and autistic spectrum disorder: is there any association? *CNS Neurol Disord Drug Targets* 15, 390–402. 10.2174/1871527315666160321104303. [PubMed: 26996178]

46. Li J, Yuan Y, Liu C, Xu Y, Xiao N, Long H, Luo Z, Meng S, Wang H, Xiao B, et al. (2022). *DNAH14* variants are associated with neurodevelopmental disorders. *Hum Mutat* 43, 940–949. 10.1002/humu.24386. [PubMed: 35438214]
47. Trost B, Walker S, Wang Z, Thiruvahindrapuram B, MacDonald JR, Sung WWL, Pereira SL, Whitney J, Chan AJS, Pellecchia G, et al. (2018). A comprehensive workflow for read depth-based identification of copy-number variation from whole-genome sequence data. *Am J Hum Genet* 102, 142–155. 10.1016/j.ajhg.2017.12.007. [PubMed: 29304372]
48. Nakka P, Pattillo Smith S, O'Donnell-Luria AH, McManus KF, 23andMe Research Team, Mountain JL, Ramachandran S, and Sathirapongsasuti JF (2019). Characterization of prevalence and health consequences of uniparental disomy in four million individuals from the general population. *Am J Hum Genet* 105, 921–932. 10.1016/j.ajhg.2019.09.016. [PubMed: 31607426]
49. Chalkia D, Singh LN, Leipzig J, Lvova M, Derbeneva O, Lakatos A, Hadley D, Hakonarson H, and Wallace DC (2017). Association between mitochondrial DNA haplogroup variation and autism spectrum disorders. *JAMA Psychiatry* 74, 1161–1168. 10.1001/jamapsychiatry.2017.2604. [PubMed: 28832883]
50. Wang Y, Picard M, and Gu Z (2016). Genetic evidence for elevated pathogenicity of mitochondrial DNA heteroplasmy in autism spectrum disorder. *PLoS Genet* 12, e1006391. 10.1371/journal.pgen.1006391. [PubMed: 27792786]
51. Doan RN, Lim ET, De Rubeis S, Betancur C, Cutler DJ, Chiochetti AG, Overman LM, Soucy A, Goetze S, Autism Sequencing Consortium, et al. (2019). Recessive gene disruptions in autism spectrum disorder. *Nat Genet* 51, 1092–1098. 10.1038/s41588-019-0433-8. [PubMed: 31209396]
52. Ozonoff S, Young GS, Carter A, Messinger D, Yirmiya N, Zwaigenbaum L, Bryson S, Carver LJ, Constantino JN, Dobkins K, et al. (2011). Recurrence risk for autism spectrum disorders: a Baby Siblings Research Consortium study. *Pediatrics* 128, e488–95. 10.1542/peds.2010-2825. [PubMed: 21844053]
53. Yuen RKC, Thiruvahindrapuram B, Merico D, Walker S, Tammimies K, Hoang N, Chrysler C, Nalpathamkalam T, Pellecchia G, Liu Y, et al. (2015). Whole-genome sequencing of quartet families with autism spectrum disorder. *Nat Med* 21, 185–191. 10.1038/nm.3792. [PubMed: 25621899]
54. Gaugler T, Klei L, Sanders SJ, Bodea CA, Goldberg AP, Lee AB, Mahajan M, Manaa D, Pawitan Y, Reichert J, et al. (2014). Most genetic risk for autism resides with common variation. *Nat Genet* 46, 881–885. 10.1038/ng.3039. [PubMed: 25038753]
55. Klei L, McClain LL, Mahjani B, Panayidou K, De Rubeis S, Grahnat A-CS, Karlsson G, Lu Y, Melhem N, Xu X, et al. (2021). How rare and common risk variation jointly affect liability for autism spectrum disorder. *Mol Autism* 12, 66. 10.1186/s13229-021-00466-2. [PubMed: 34615521]
56. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, Pallesen J, Agerbo E, Andreassen OA, Anney R, et al. (2019). Identification of common genetic risk variants for autism spectrum disorder. *Nat Genet* 51, 431–444. 10.1038/s41588-019-0344-8. [PubMed: 30804558]
57. Weiner DJ, Wigdor EM, Ripke S, Walters RK, Kosmicki JA, Grove J, Samocha KE, Goldstein JJ, Okbay A, Bybjerg-Grauholm J, et al. (2017). Polygenic transmission disequilibrium confirms that common and rare variation act additively to create risk for autism spectrum disorders. *Nat Genet* 49, 978–985. 10.1038/ng.3863. [PubMed: 28504703]
58. Perkel JM (2021). Reactive, reproducible, collaborative: computational notebooks evolve. *Nature* 593, 156–157. 10.1038/d41586-021-01174-w. [PubMed: 33941927]
59. Pimentel JF, Murta L, Braganholo V, and Freire J (2019). A large-scale study about quality and reproducibility of Jupyter notebooks. In 2019 IEEE/ACM 16th International Conference on Mining Software Repositories (MSR), pp. 507–517. 10.1109/MSR.2019.00077.
60. Stein LD, Knoppers BM, Campbell P, Getz G, and Korbel JO (2015). Data analysis: Create a cloud commons. *Nature* 523, 149–151. 10.1038/523149a. [PubMed: 26156357]
61. Dolzhenko E, Deshpande V, Schlesinger F, Krusche P, Petrovski R, Chen S, Emig-Agius D, Gross A, Narzisi G, Bowman B, et al. (2019). ExpansionHunter: a sequence-graph-based tool to analyze variation in short tandem repeat regions. *Bioinformatics* 35, 4754–4756. 10.1093/bioinformatics/btz431. [PubMed: 31134279]

62. Dolzhenko E, Bennett MF, Richmond PA, Trost B, Chen S, van Vugt JJFA, Nguyen C, Narzisi G, Gainullin VG, Gross AM, et al. (2020). ExpansionHunter Denovo: a computational method for locating known and novel repeat expansions in short-read sequencing data. *Genome Biol* 21, 102. 10.1186/s13059-020-02017-z. [PubMed: 32345345]
63. Hoang N, Cytrynbaum C, and Scherer SW (2018). Communicating complex genomic information: A counselling approach derived from research experience with Autism Spectrum Disorder. *Patient Educ Couns* 101, 352–361. 10.1016/j.pec.2017.07.029. [PubMed: 28803755]
64. Vorstman J, and Scherer SW (2021). What a finding of gene copy number variation can add to the diagnosis of developmental neuropsychiatric disorders. *Curr Opin Genet Dev* 68, 18–25. 10.1016/j.gde.2020.12.017. [PubMed: 33454514]
65. Werling DM, Brand H, An JY, Stone MR, Zhu L, Glessner JT, Collins RL, Dong S, Layer RM, Markenscoff-Papadimitriou E, et al. (2018). An analytical framework for whole-genome sequence association studies and its implications for autism spectrum disorder. *Nature Genetics* 50, 727–736. 10.1038/s41588-018-0107-y. [PubMed: 29700473]
66. An J-Y, Lin K, Zhu L, Werling DM, Dong S, Brand H, Wang HZ, Zhao X, Schwartz GB, Collins RL, et al. (2018). Genome-wide *de novo* risk score implicates promoter variation in autism spectrum disorder. *Science* 362, eaat6576. 10.1126/science.aat6576. [PubMed: 30545852]
67. Lambert SA, Abraham G, and Inouye M (2019). Towards clinical utility of polygenic risk scores. *Hum Mol Genet* 28, R133–R142. 10.1093/hmg/ddz187. [PubMed: 31363735]
68. Lewis CM, and Vassos E (2020). Polygenic risk scores: from research tools to clinical instruments. *Genome Med* 12, 44. 10.1186/s13073-020-00742-5. [PubMed: 32423490]
69. D’Abate L, Walker S, Yuen RKC, Tammimies K, Buchanan JA, Davies RW, Thiruvahindrapuram B, Wei J, Brian J, Bryson SE, et al. (2019). Predictive impact of rare genomic copy number variations in siblings of individuals with autism spectrum disorders. *Nat Commun* 10, 5519. 10.1038/s41467-019-13380-2. [PubMed: 31801954]
70. Antaki D, Guevara J, Maihofer AX, Klein M, Gujral M, Grove J, Carey CE, Hong O, Arranz MJ, Hervas A, et al. (2022). A phenotypic spectrum of autism is attributable to the combined effects of rare variants, polygenic risk and sex. *Nat Genet*. 10.1038/s41588-022-01064-5.
71. Costain G, Cohn RD, Scherer SW, and Marshall CR (2021). Genome sequencing as a diagnostic test. *CMAJ* 193, E1626–E1629. 10.1503/cmaj.210549. [PubMed: 34697096]
72. Bradshaw J, Steiner AM, Gengoux G, and Koegel LK (2015). Feasibility and effectiveness of very early intervention for infants at-risk for autism spectrum disorder: a systematic review. *J Autism Dev Disord* 45, 778–794. 10.1007/s10803-014-2235-2. [PubMed: 25218848]
73. Baribeau D, and Anagnostou E (2022). Novel treatments for autism spectrum disorder based on genomics and systems biology. *Pharmacol Ther* 230, 107939. 10.1016/j.pharmthera.2021.107939. [PubMed: 34174273]
74. Paulsen B, Velasco S, Kedaigle AJ, Pigoni M, Quadrato G, Deo AJ, Adiconis X, Uzquiano A, Sartore R, Yang SM, et al. (2022). Autism genes converge on asynchronous development of shared neuron classes. *Nature* 602, 268–273. 10.1038/s41586-021-04358-6. [PubMed: 35110736]
75. Krupp DR, Barnard RA, Duffourd Y, Evans SA, Mulqueen RM, Bernier R, Rivière J-B, Fombonne E, and O’Roak BJ (2017). Exonic mosaic mutations contribute risk for autism spectrum disorder. *Am J Hum Genet* 101, 369–390. 10.1016/j.ajhg.2017.07.016. [PubMed: 28867142]
76. Lim ET, Uddin M, De Rubeis S, Chan Y, Kamumbu AS, Zhang X, D’Gama AM, Kim SN, Hill RS, Goldberg AP, et al. (2017). Rates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder. *Nat Neurosci* 20, 1217–1224. 10.1038/nn.4598. [PubMed: 28714951]
77. Siu MT, Butcher DT, Turinsky AL, Cytrynbaum C, Stavropoulos DJ, Walker S, Caluseriu O, Carter M, Lou Y, Nicolson R, et al. (2019). Functional DNA methylation signatures for autism spectrum disorder genomic risk loci: 16p11.2 deletions and *CHD8* variants. *Clin Epigenetics* 11, 103. 10.1186/s13148-019-0684-3. [PubMed: 31311581]
78. Siu MT, Goodman SJ, Yellan I, Butcher DT, Jangjoo M, Grafodatskaya D, Rajendram R, Lou Y, Zhang R, Zhao C, et al. (2021). DNA methylation of the oxytocin receptor across neurodevelopmental disorders. *J Autism Dev Disord* 51, 3610–3623. 10.1007/s10803-020-04792-x. [PubMed: 33394241]

79. Regier AA, Farjoun Y, Larson DE, Krasheninina O, Kang HM, Howrigan DP, Chen B-J, Kher M, Banks E, Ames DC, et al. (2018). Functional equivalence of genome sequencing analysis pipelines enables harmonized variant calling across human genetics projects. *Nat Commun* 9, 4038. 10.1038/s41467-018-06159-4. [PubMed: 30279509]
80. Kendig KI, Baheti S, Bockol MA, Drucker TM, Hart SN, Heldenbrand JR, Hernaez M, Hudson ME, Kalmbach MT, Klee EW, et al. (2019). Sentieon DNaseq variant calling workflow demonstrates strong computational performance and accuracy. *Front Genet* 10, 736. 10.3389/fgene.2019.00736. [PubMed: 31481971]
81. Li H, and Durbin R (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 25, 1754–1760. 10.1093/bioinformatics/btp324. [PubMed: 19451168]
82. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernysky A, Garimella K, Altshuler D, Gabriel S, Daly M, et al. (2010). The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 20, 1297–1303. 10.1101/gr.107524.110. [PubMed: 20644199]
83. Byrska-Bishop M, Evani US, Zhao X, Basile AO, Abel HJ, Regier AA, Corvelo A, Clarke WE, Musunuri R, Nagulapalli K, et al. (2022). High-coverage whole-genome sequencing of the expanded 1000 Genomes Project cohort including 602 trios. *Cell* 185, 3426–3440.e19. 10.1016/j.cell.2022.08.004. [PubMed: 36055201]
84. Wang K, Li M, and Hakonarson H (2010). ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res* 38, e164. 10.1093/nar/gkq603. [PubMed: 20601685]
85. Ramu A, Noordam MJ, Schwartz RS, Wuster A, Hurles ME, Cartwright RA, and Conrad DF (2013). DeNovoGear: *de novo* indel and point mutation discovery and phasing. *Nat Methods* 10, 985–987. 10.1038/nmeth.2611. [PubMed: 23975140]
86. Alexander DH, Novembre J, and Lange K (2009). Fast model-based estimation of ancestry in unrelated individuals. *Genome Res* 19, 1655–1664. 10.1101/gr.094052.109. [PubMed: 19648217]
87. Harrison SM, Biesecker LG, and Rehm HL (2019). Overview of specifications to the ACMG/AMP variant interpretation guidelines. *Curr Protoc Hum Genet* 103, e93. 10.1002/cphg.93. [PubMed: 31479589]
88. Zhu M, Need AC, Han Y, Ge D, Maia JM, Zhu Q, Heinzen EL, Cirulli ET, Pelak K, He M, et al. (2012). Using ERDS to infer copy-number variants in high-coverage genomes. *Am J Hum Genet* 91, 408–421. 10.1016/j.ajhg.2012.07.004. [PubMed: 22939633]
89. Abyzov A, Urban AE, Snyder M, and Gerstein M (2011). CNVnator: an approach to discover, genotype, and characterize typical and atypical CNVs from family and population genome sequencing. *Genome Res* 21, 974–984. 10.1101/gr.114876.110. [PubMed: 21324876]
90. Kosugi S, Momozawa Y, Liu X, Terao C, Kubo M, and Kamatani Y (2019). Comprehensive evaluation of structural variation detection algorithms for whole genome sequencing. *Genome Biol* 20, 117. 10.1186/s13059-019-1720-5. [PubMed: 31159850]
91. Rausch T, Zichner T, Schlattl A, Stütz AM, Benes V, and Korbel JO (2012). DELLY: Structural variant discovery by integrated paired-end and split-read analysis. *Bioinformatics* 28, 333–339. 10.1093/bioinformatics/bts378.
92. Cameron DL, Schröder J, Penington JS, Do H, Molania R, Dobrovic A, Speed TP, and Papenfuss AT (2017). GRIDSS: sensitive and specific genomic rearrangement detection using positional de Bruijn graph assembly. *Genome Res* 27, 2050–2060. 10.1101/gr.222109.117. [PubMed: 29097403]
93. Layer RM, Chiang C, Quinlan AR, and Hall IM (2014). LUMPY: a probabilistic framework for structural variant discovery. *Genome Biol* 15, R84. 10.1186/gb-2014-15-6-r84. [PubMed: 24970577]
94. Chen X, Schulz-Trieglaff O, Shaw R, Barnes B, Schlesinger F, Källberg M, Cox AJ, Kruglyak S, and Saunders CT (2016). Manta: Rapid detection of structural variants and indels for germline and cancer sequencing applications. *Bioinformatics* 32, 1220–1222. 10.1093/bioinformatics/btv710. [PubMed: 26647377]

95. Bartenhagen C, and Dugas M (2016). Robust and exact structural variation detection with paired-end and soft-clipped alignments: SoftSV compared with eight algorithms. *Brief Bioinform* 17, 51–62. 10.1093/bib/bbv028. [PubMed: 25998133]
96. Wala JA, Bandopadhyay P, Greenwald NF, O'Rourke R, Sharpe T, Stewart C, Schumacher S, Li Y, Weischenfeldt J, Yao X, et al. (2018). SvABA: genome-wide detection of structural variants and indels by local assembly. *Genome Res* 28, 581–591. 10.1101/gr.221028.117. [PubMed: 29535149]
97. Kronenberg ZN, Osborne EJ, Cone KR, Kennedy BJ, Domyan ET, Shapiro MD, Elde NC, and Yandell M (2015). Wham: identifying structural variants of biological consequence. *PLoS Comput Biol* 11, e1004572. 10.1371/journal.pcbi.1004572. [PubMed: 26625158]
98. Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, Axelrod N, Huang J, Kirkness EF, Denisov G, et al. (2007). The diploid genome sequence of an individual human. *PLoS Biol* 5, e254. 10.1371/journal.pbio.0050254. [PubMed: 17803354]
99. Zook JM, Hansen NF, Olson ND, Chapman L, Mullikin JC, Xiao C, Sherry S, Koren S, Phillippy AM, Boutros PC, et al. (2020). A robust benchmark for detection of germline large deletions and insertions. *Nat Biotechnol* 38, 1347–1355. 10.1038/s41587-020-0538-8. [PubMed: 32541955]
100. Sedlazeck FJ, Rescheneder P, Smolka M, Fang H, Nattestad M, von Haeseler A, and Schatz MC (2018). Accurate detection of complex structural variations using single-molecule sequencing. *Nat Methods* 15, 461–468. 10.1038/s41592-018-0001-7. [PubMed: 29713083]
101. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 17, 405–424. 10.1038/gim.2015.30. [PubMed: 25741868]
102. Riggs ER, Andersen EF, Cherry AM, Kantarci S, Kearney H, Patel A, Raca G, Ritter DI, South ST, Thorland EC, et al. (2020). Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). *Genet Med* 22, 245–257. 10.1038/s41436-019-0686-8. [PubMed: 31690835]
103. Kent WJ (2002). BLAT-the BLAST-like alignment tool. *Genome Res* 12, 656–664. 10.1101/gr.229202. [PubMed: 11932250]
104. Speir ML, Zweig AS, Rosenbloom KR, Raney BJ, Paten B, Nejad P, Lee BT, Learned K, Karolchik D, Hinrichs AS, et al. (2016). The UCSC Genome Browser database: 2016 update. *Nucleic Acids Res* 44, D717–725. 10.1093/nar/gkv1275. [PubMed: 26590259]
105. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, Maller J, Sklar P, de Bakker PIW, Daly MJ, et al. (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 81, 559–575. 10.1086/519795. [PubMed: 17701901]
106. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, Flicek P, and Cunningham F (2016). The Ensembl Variant Effect Predictor. *Genome Biol* 17, 122. 10.1186/s13059-016-0974-4. [PubMed: 27268795]
107. Zerbino DR, Wilder SP, Johnson N, Juettemann T, and Flicek PR (2015). The Ensembl Regulatory Build. *Genome Biol* 16, 56. 10.1186/s13059-015-0621-5. [PubMed: 25887522]
108. Fishilevich S, Nudel R, Rappaport N, Hadar R, Plaschkes I, Iny Stein T, Rosen N, Kohn A, Twik M, Safran M, et al. (2017). GeneHancer: genome-wide integration of enhancers and target genes in GeneCards. *Database (Oxford)* 2017. 10.1093/database/bax028.
109. Chèneby J, Ménétrier Z, Mestdagh M, Rosnet T, Douida A, Rhalloussi W, Bergon A, Lopez F, and Ballester B (2020). ReMap 2020: a database of regulatory regions from an integrative analysis of human and arabidopsis DNA-binding sequencing experiments. *Nucleic Acids Res* 48, D180–D188. 10.1093/nar/gkz945. [PubMed: 31665499]
110. Volders P-J, Helsens K, Wang X, Menten B, Martens L, Gevaert K, Vandesompele J, and Mestdagh P (2013). LNCipedia: a database for annotated human lncRNA transcript sequences and structures. *Nucleic Acids Res* 41, D246–251. 10.1093/nar/gks915. [PubMed: 23042674]

111. Kuksa PP, Amlie-Wolf A, Katani Ž, Valladares O, Wang L-S, and Leung YY (2019). DASHR 2.0: integrated database of human small non-coding RNA genes and mature products. *Bioinformatics* 35, 1033–1039. 10.1093/bioinformatics/bty709. [PubMed: 30668832]
112. Wang J, Song L, Grover D, Azrak S, Batzer MA, and Liang P (2006). dbRIP: a highly integrated database of retrotransposon insertion polymorphisms in humans. *Hum Mutat* 27, 323–329. 10.1002/humu.20307. [PubMed: 16511833]
113. Dixon JR, Selvaraj S, Yue F, Kim A, Li Y, Shen Y, Hu M, Liu JS, and Ren B (2012). Topological domains in mammalian genomes identified by analysis of chromatin interactions. *Nature* 485, 376–380. 10.1038/nature11082. [PubMed: 22495300]
114. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O'Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB, et al. (2016). Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 536, 285–291. 10.1038/nature19057. [PubMed: 27535533]
115. Pinto D, Delaby E, Merico D, Barbosa M, Merikangas A, Klei L, Thiruvahindrapuram B, Xu X, Ziman R, Wang Z, et al. (2014). Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. *Am J Hum Genet* 94, 677–694. 10.1016/j.ajhg.2014.03.018. [PubMed: 24768552]
116. Sanders SJ, He X, Willsey AJ, Ercan-Sencicek AG, Samocha KE, Cicek AE, Murtha MT, Bal VH, Bishop SL, Dong S, et al. (2015). Insights into autism spectrum disorder genomic architecture and biology from 71 risk loci. *Neuron* 87, 1215–1233. 10.1016/j.neuron.2015.09.016. [PubMed: 26402605]
117. Riggs ER, Church DM, Hanson K, Horner VL, Kaminsky EB, Kuhn RM, Wain KE, Williams ES, Aradhya S, Kearney HM, et al. (2012). Towards an evidence-based process for the clinical interpretation of copy number variation. *Clin Genet* 81, 403–412. 10.1111/j.1399-0004.2011.01818.x. [PubMed: 22097934]
118. Li H (2011). A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. *Bioinformatics* 27, 2987–2993. 10.1093/bioinformatics/btr509. [PubMed: 21903627]
119. Weissensteiner H, Pacher D, Kloss-Brandstätter A, Forer L, Specht G, Bandelt H-J, Kronenberg F, Salas A, and Schönherr S (2016). HaploGrep 2: mitochondrial haplogroup classification in the era of high-throughput sequencing. *Nucleic Acids Res* 44, W58–63. 10.1093/nar/gkw233. [PubMed: 27084951]
120. Lott MT, Leipzig JN, Derbeneva O, Xie HM, Chalkia D, Sarmady M, Procaccio V, and Wallace DC (2013). mtDNA variation and analysis using Mitomap and Mitomaster. *Curr Protoc Bioinformatics* 44, 1.23.1–26. 10.1002/0471250953.bi0123s44.
121. Dupuis A, Moon MJ, Brian J, Georgiades S, Levy T, Anagnostou E, Nicolson R, Schachar R, and Crosbie J (2021). Concurrent validity of the ABAS-II questionnaire with the Vineland II interview for adaptive behavior in a pediatric ASD sample: high correspondence despite systematically lower scores. *J Autism Dev Disord* 51, 1417–1427. 10.1007/s10803-020-04597-y. [PubMed: 32776267]
122. Lord C, Rutter M, DiLavore P, Risi S, Gotham K, and Bishop S (2012). *Autism Diagnostic Observation Schedule–2nd Edition (ADOS-2)*. (Western Psychological Services).
123. Hus V, and Lord C (2014). The autism diagnostic observation schedule, module 4: revised algorithm and standardized severity scores. *J Autism Dev Disord* 44, 1996–2012. 10.1007/s10803-014-2080-3. [PubMed: 24590409]
124. Samocha KE, Kosmicki JA, Karczewski KJ, O'Donnell-Luria AH, Pierce-Hoffman E, MacArthur DG, Neale BM, and Daly MJ (2017). Regional missense constraint improves variant deleteriousness prediction. *bioRxiv*, 148353. 10.1101/148353.
125. Liu X, Wu C, Li C, and Boerwinkle E (2016). dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice-site SNVs. *Hum Mutat* 37, 235–241. 10.1002/humu.22932. [PubMed: 26555599]
126. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT, et al. (2010). The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. *Nucleic Acids Res* 38, W214–220. 10.1093/nar/gkq537. [PubMed: 20576703]

127. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, and Ideker T (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res* 13, 2498–2504. 10.1101/gr.1239303. [PubMed: 14597658]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

- New MSSNG release contains WGS from 11,312 individuals from families with ASD
- Extensive variant data available, including SNVs/indels, SVs, tandem repeats & PRS
- Annotation reveals 134 ASD-associated genes, plus SVs not detectable without WGS
- Rare, dominant variation has a prominent role in multiplex ASD




Figure 1. Data Processing and Analysis Workflow.

The Genetic Variant Data section applies to all samples except 1,738 sequenced by Complete Genomics, which used proprietary software. Although CNVs and TREs are types of SVs, they are shown separately because different methods were used for their detection. CNVs include deletions and duplications 1 kb, while SVs include deletions, duplications, insertions, and inversions 50 bp.




Figure 2. Identification of ASD-Associated Genes Using TADA+. (A) Exonic *de novo* variants per individual in ASC, MSSNG, and SPARK. (B) ASD-associated genes discovered only in the previous TADA+ analysis⁸ (“ASC”), only in the current analysis (“ASC+MSSNG+SPARK”), or both. (C) Distribution of SFARI Gene scores for the newly discovered genes. (D) FDRs for the 134 ASD-associated genes. Blue dots: genes also identified in the previous TADA+ analysis; green dots: new genes. Genes with FDR calculated as zero were assigned a value of 10^{-17} . The blue line represents FDR=0.1. (E) Evidence supporting the new ASD-associated genes. “Case-control difference” represents PTVs in cases minus controls. The y-axis is truncated at -3; the value for MIB1 is -9. (F) pLI values for the new genes. (G) Network diagram of TADA+ genes. Only genes connected to gene networks are shown. Nodes represent genes, and edges represent protein-protein and pathway interactions between gene pairs. Modules are

indicated by blue circles, with module labels derived from GO term enrichment tests (bold: significantly enriched).




Figure 4. Genomic Architecture of Rare Variants in ASD.

(A) Burden analysis of sequence-level rare coding variants. Left, individuals with ASD versus non-ASD siblings. Middle, probands from MSSNG MPX families versus those from either SSC SPX families (having exactly one individual with ASD and at least one sibling without) or MSSNG non-MPX families (having exactly one individual with ASD and no siblings). Right, same as middle except siblings with ASD instead of probands. Burdens for other rare ASD-associated variants are given in Table S5A. Compared with sequence-level variants, many SV types had very high ORs, including

chromosomal abnormalities (OR=4.9), genomic disorders (OR=8.3), and SVs impacting ASD genes (OR=24) (comparisons between MSSNG individuals with ASD and SSC non-ASD siblings). (B) Yield of ASD-associated rare variants (top) and stratified by variant type (bottom). “Multiple” indicates individuals with ASD-associated variants in more than one category. (C) Distributions of consensus phenotype measures for individuals with ASD having each type of ASD-associated rare variant, or no variant. *Nominally significant ($p < 0.05$); **: significant after multiple testing correction.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 5. Detailed View of the Genomic Architecture of Rare Variants in ASD. (A) *De novo* or rare inherited (gnomAD allele frequency $<10^{-4}$) PTVs and *de novo* DMIs variants in autosomal genes identified by the TADA+ analysis or evaluated as definitive by EAGLE⁴². For X-linked genes, we identified hemizygous PTVs in males with frequency $<10^{-4}$ in constrained genes (pLI > 0.95) found in the Genomics England neurology and neurodevelopmental disorders panel. (B) Recessive events (PTV-PTV events in genes from the Genomics England panel). (C) Chromosomal abnormalities. (D) Genomic disorders. (E) Large or gene-rich CNVs other than genomic disorders. (F) SVs disrupting ASD-associated genes. (G) UPDs. (H) TREs identified previously³¹. (I) Pathogenic mtDNA variants. CPEO, chronic progressive external ophthalmoplegia; MNGIE, mitochondrial neurogastrointestinal encephalomyopathy.




Figure 6. PRS Analysis. (A) Reproducibility in ten pairs of monozygotic (MZ) twins from MSSNG. (B) PRS distributions in MSSNG, SSC, and 1000G. (C) Comparison between individuals with ASD and non-ASD siblings. (D) Over-transmission of polygenic risk from parents to children. (E) Odds ratio of individuals with ASD to those without in each PRS decile, relative to decile 1, in MSSNG and SSC combined. (F) Pedigrees showing the PRS for each individual in two large MPX families. (G) Association between PRS and the four consensus phenotype measures.

Table 1.
Comparison Between the Previous Version of MSSNG⁷ and the Current Release.

Multiplex families are defined as those with two or more children with ASD and do not include families having non-sibling members with ASD.

	Previous version	Current version
Participants		
Total individuals	5,152	11,312
Individuals with ASD	2,613	5,100
Families	2,063	4,258
Multiplex families	489	777
Families having non-sibling members with ASD	1	10
Genetic variant data		
Reference genome	GRCh37	GRCh38
Single-nucleotide variants and indels	Single sample	Joint-called *
Copy number variants	Not available	Available
Structural variants	Not available	Available
Tandem repeat expansions	Not available	Available *
Polygenic risk scores	Not available	Available *
Phenotype data		
Consensus phenotype measures	Not available	Available
Data access		
Phenotype Data Explorer	Not available	Available
Terra integration	Not available	Available
Researchers approved for access		
Researchers	75	342
Institutions	17	65
Countries	4	20

* Only for samples sequenced on Illumina platforms.

Key resources table

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Deposited data		
MSSNG	This paper	https://research.mss.ng/
Simons Simplex Collection	SFARI	https://www.sfari.org/resource/sfari-base/
SPARK	SFARI	https://www.sfari.org/resource/sfari-base/
1000 Genomes Project	1000 Genomes Project Consortium	https://www.internationalgenome.org/
Human Reference Genome Build 38 (GRCh38)	Genome Reference Consortium	https://www.ncbi.nlm.nih.gov/grc/human
Genome aggregation database (gnomAD)	Broad Institute	https://gnomad.broadinstitute.org/
dbNSFP	Liu et al. ¹²⁵	https://sites.google.com/site/jpopgen/dbNSFP
ASC variant-level data	Autism Sequencing Consortium	https://asc.broadinstitute.org
Ensembl Regulatory Build	Ensembl	http://useast.ensembl.org/info/genome/funcgen/regulatory_build.html
GeneHancer	Fishilevich et al. ¹⁰⁸	https://genome.ucsc.edu/
ReMap2020	Chèneby et al. ¹⁰⁹	http://remap.univ-amu.fr
LNCipedia	Volders et al. ¹¹⁰	https://lncipedia.org
DASHR	Kuksa et al. ¹¹¹	https://dashr2.lisanwanglab.org
dbRIP	Wang et al. ¹¹²	https://dbrip.brocku.ca
Software and algorithms		
Sentieon	Kendig et al. ⁸⁰	https://www.sentieon.com/products/
DeNovoGear	Ramu et al. ⁸⁵	https://github.com/ultimatesource/denovogear
ADMIXTURE	Alexander et al. ⁸⁶	https://dalexander.github.io/admixture/publications.html
Genomic ancestry inference with deep learning	Google	https://cloud.google.com/blog/products/gcp/genomic-ancestry-inference-with-deep-learning
BWA	Li and Durbin ⁸¹	http://bio-bwa.sourceforge.net/
SAMtools	Li et al. ¹¹⁸	http://www.htslib.org/
HaploGrep	Weissensteiner et al. ¹¹⁹	https://haplogrep.1-med.ac.at/
MitoMaster	Lott et al. ¹²⁰	https://www.mitomap.org/foswiki/bin/view/MITOMASTER/WebHome
ERDS	Zhu et al. ⁸⁸	https://github.com/igm-team/ERDS
CNVnator	Abyzov et al. ⁸⁹	https://github.com/abyzovlab/CNVnator
DELLY	Rausch et al. ⁹¹	https://github.com/dellytools/delly
Manta	Chen et al. ⁹⁴	https://github.com/Illumina/manta
ANNOVAR	Wang et al. ⁸⁴	https://annovar.openbioinformatics.org/en/latest/
Variant Effect Predictor (VEP)	McLaren et al. ¹⁰⁶	https://useast.ensembl.org/info/docs/tools/vep/index.html
TADA	He et al. ²⁴	http://www.compgen.pitt.edu/TADA/TADA_guide.html
TADA+	Satterstrom et al. ⁸	Personal communication
PLINK	Purcell et al. ¹⁰⁵	https://zzz.bwh.harvard.edu/plink/

REAGENT or RESOURCE	SOURCE	IDENTIFIER
GeneMANIA	Warde-Farley et al. ¹²⁶	https://genemania.org/
Custom scripts	This paper	10.5281/zenodo.7086706

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript